Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,1.8504339456558228,2.0239129066467285,1.8504339456558228,1.8504339456558228,3437,0.0,0.0,,,,,,,,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-28,1.9660860300064087,2.106520891189575,1.7760859727859497,2.106520891189575,23486,0.0,0.0,,,,,,,100.0,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-29,1.8999990224838257,1.9826079607009888,1.8504339456558228,1.883478045463562,11412,0.0,0.0,,,,,,,51.60058191791787,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-30,1.817391037940979,1.8999990224838257,1.817391037940979,1.817391037940979,18051,0.0,0.0,,,,,,,44.69759887175424,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-01,1.7347819805145264,1.7760859727859497,1.7265210151672363,1.7265210151672363,34086,0.0,0.0,,,,,,,37.307253726256896,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-04,1.7265210151672363,1.7347819805145264,1.6686949729919434,1.7265210151672363,32101,0.0,0.0,,,,,,,37.307253726256896,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-05,1.7265210151672363,1.7760859727859497,1.7265210151672363,1.7760859727859497,8620,0.0,0.0,,,,,,,43.24359519355811,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-06,1.9743469953536987,1.9743469953536987,1.759564995765686,1.767825961112976,8694,0.0,0.0,,,,,,,42.52099904123814,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-07,1.751304030418396,1.9413039684295654,1.751304030418396,1.8752169609069824,7738,0.0,0.0,,,,,,,53.41915710226459,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-08,1.751304030418396,1.8669559955596924,1.751304030418396,1.8669559955596924,3487,0.0,0.0,1.8396950840950013,,,1.4818168347773533,,,52.593080917082126,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-11,1.751304030418396,1.833912968635559,1.6397819519042969,1.8091299533843994,7997,0.0,0.0,1.8355646848678588,,,-1.440141646948413,,,47.1022046450994,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-12,1.8091299533843994,1.8091299533843994,1.8091299533843994,1.8091299533843994,276,0.0,0.0,1.8058255910873413,,,0.18298346824670098,,,47.1022046450994,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-13,1.8091299533843994,1.8091299533843994,1.8091299533843994,1.8091299533843994,79,0.0,0.0,1.7983907818794251,,,0.5971545013009467,,,47.1022046450994,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-14,1.8091299533843994,1.8586950302124023,1.4043469429016113,1.8586950302124023,6121,0.0,0.0,1.8025211811065673,,,3.1164043837393294,,,52.42013467286711,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-15,1.8586950302124023,2.1147820949554443,1.6604340076446533,2.1147820949554443,1935,0.0,0.0,1.8413472890853881,,,14.849713983388405,,,69.48782501499869,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-18,2.1147820949554443,2.1147820949554443,1.5199990272521973,1.6604340076446533,110500,0.0,0.0,1.83473858833313,,,-9.500240622661854,,,41.22954077697062,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-19,1.6604340076446533,1.7265210151672363,1.5282599925994873,1.6480430364608765,10082,0.0,0.0,1.8219342947006225,,,-9.544321040859467,,,40.74292011024793,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-20,1.7265210151672363,1.7265210151672363,1.5282599925994873,1.6480430364608765,12961,0.0,0.0,1.8099560022354126,,,-8.945685175471846,,,40.74292011024792,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-21,1.5076080560684204,1.6604340076446533,1.4539129734039307,1.4539129734039307,144893,0.0,0.0,1.7678256034851074,,,-17.756990817551603,,,33.54827929469428,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-22,1.4993469715118408,1.5654339790344238,1.4580429792404175,1.561303973197937,22533,0.0,0.0,1.7372604012489319,,,-10.128385354578867,,,39.8735919608355,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-25,1.685217022895813,1.685217022895813,1.4580429792404175,1.6480430364608765,94307,0.0,0.0,1.7211517095565796,,,-4.247660022633223,,,44.471137791095735,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-26,1.5695650577545166,1.6686949729919434,1.5034780502319336,1.63565194606781,13055,0.0,0.0,1.7038039088249206,,,-3.999988637431499,,,43.954079534022604,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-27,1.6604340076446533,1.6686949729919434,1.5736949443817139,1.6604340076446533,17181,0.0,0.0,1.688934314250946,,,-1.6874727670467664,,,45.32330842697268,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-28,1.685217022895813,1.685217022895813,1.5695650577545166,1.676956057548523,68974,0.0,0.0,1.670760416984558,,,0.370827588502906,,,46.2658352798369,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-29,1.676956057548523,1.676956057548523,1.5241299867630005,1.5736949443817139,49654,0.0,0.0,1.616651701927185,,,-2.6571436193871047,,,41.45593795101999,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-01,1.6686949729919434,1.6686949729919434,1.5282599925994873,1.5282599925994873,25797,0.0,0.0,1.6034343004226685,,,-4.688331028179024,,,39.509609682142454,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-02,1.5365209579467773,1.5654339790344238,1.4580429792404175,1.4910860061645508,51822,0.0,0.0,1.5877385973930358,,,-6.08743727633644,,,37.94010845053096,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-03,1.6397819519042969,1.6397819519042969,1.5489130020141602,1.5571730136871338,1537,0.0,0.0,1.5786515951156617,,,-1.360565022388884,,,42.3264011429733,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-04,1.4828259944915771,1.5695650577545166,1.4828259944915771,1.5323909521102905,24760,0.0,0.0,1.5864993929862976,,,-3.410555409930397,,,41.15182355767523,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-05,1.6315209865570068,1.6315209865570068,1.486956000328064,1.5282599925994873,31724,0.0,0.0,1.5831949949264525,,,-3.4698822635879574,,,40.94783794790037,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-08,1.5282599925994873,1.5282599925994873,1.5034780502319336,1.5282599925994873,13763,0.0,0.0,1.5712166905403138,,,-2.733976681857574,,,40.94783794790038,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-09,1.6067390441894531,1.6067390441894531,1.4910860061645508,1.561303973197937,6415,0.0,0.0,1.5637818932533265,,,-0.15845688366645386,,,43.54399737120662,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-10,1.486956000328064,1.544782042503357,1.4249989986419678,1.5406520366668701,2410,0.0,0.0,1.5518036961555481,,,-0.7186256558291001,,,42.29255016078107,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-11,1.5406520366668701,1.5406520366668701,1.429129958152771,1.4539129734039307,17381,0.0,0.0,1.529499387741089,,,-4.941905498163784,,,37.4272386177877,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-12,1.4539129734039307,1.5076080560684204,1.4539129734039307,1.5034780502319336,11427,0.0,0.0,1.5224776983261108,,,-1.247942621101536,,,41.564111471905534,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-15,1.5654339790344238,1.5695650577545166,1.5034780502319336,1.5076080560684204,115347,0.0,0.0,1.5204125046730042,,,-0.8421693826661599,,,41.90874472398248,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-16,1.5902169942855835,1.5902169942855835,1.5076080560684204,1.5076080560684204,7252,0.0,0.0,1.522064709663391,,,-0.9498054519750179,,,41.90874472398248,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-17,1.544782042503357,1.544782042503357,1.544782042503357,1.544782042503357,38,0.0,0.0,1.5208256125450135,,,1.575225309248558,,,45.27773259694937,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-18,1.5943470001220703,1.5984779596328735,1.4249989986419678,1.5819560289382935,7263,0.0,0.0,1.5257821202278137,,,3.681646806956454,,,48.49455101950682,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-19,1.5819560289382935,1.5943470001220703,1.486956000328064,1.486956000328064,3206,0.0,0.0,1.5216517210006715,1.6704505503177642,,-2.280135473430861,-8.907706324427696,,41.74150311331651,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-22,1.6067390441894531,1.6067390441894531,1.561303973197937,1.5860860347747803,8483,0.0,0.0,1.5274343252182008,1.6638418525457381,,3.839884215525983,-8.198346923346646,,49.62451737266885,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-23,1.6026079654693604,1.751304030418396,1.5984779596328735,1.751304030418396,24613,0.0,0.0,1.5464343309402466,1.6549614310264587,,13.247875799135075,-6.557681529707924,,59.46834772372622,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-24,1.7347819805145264,1.7347819805145264,1.6067390441894531,1.61086905002594,10553,0.0,0.0,1.5534560322761535,1.648146206140518,,3.695825086575757,-5.745253273743331,,50.44503585973497,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-25,1.7265210151672363,1.7760859727859497,1.5819560289382935,1.676956057548523,69435,0.0,0.0,1.5757603406906129,1.6446353316307067,,6.422024608993443,-4.187857916915975,,53.983532931442056,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-26,1.7347819805145264,1.7347819805145264,1.6439130306243896,1.676956057548523,1107,0.0,0.0,1.5931081414222716,1.6433962076902389,,5.263165377548997,-3.060008659667416,,53.983532931442056,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-29,1.6521730422973633,1.6521730422973633,1.5076080560684204,1.5282599925994873,20243,0.0,0.0,1.5951733350753785,1.6384396821260452,,-4.194738026556172,-2.6407042946203614,,45.50462417929421,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-30,1.4373910427093506,1.61086905002594,1.4332599639892578,1.61086905002594,30464,0.0,0.0,1.6054994344711304,1.634309259057045,,0.3344514136548629,-1.7628135205289763,,50.18569890719307,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-31,1.61086905002594,1.61086905002594,1.4456520080566406,1.4580429792404175,80616,0.0,0.0,1.5968255281448365,1.626564684510231,,-8.691152944282779,-1.828341451686518,,42.8521671593426,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-01,1.478695034980774,1.478695034980774,1.3382600545883179,1.4456520080566406,10026,0.0,0.0,1.5831951260566712,1.6158255606889724,,-8.687692106696593,-2.019428051279737,,42.31229324143057,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-02,1.354781985282898,1.4043469429016113,1.296955943107605,1.4043469429016113,39056,0.0,0.0,1.574934220314026,1.6042603343725204,,-10.831390620136583,-1.8280146576063547,,40.48142135137577,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-05,1.4043469429016113,1.4043469429016113,1.2721730470657349,1.3960859775543213,52056,0.0,0.0,1.55593421459198,1.5939342349767684,,-10.273457292638582,-2.3840394133539897,,40.1076288774226,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-06,1.5654339790344238,1.5654339790344238,1.2391300201416016,1.3754340410232544,102287,0.0,0.0,1.5183472156524658,1.5830918371677398,,-9.412417209709083,-4.089757776220148,,39.134764744585965,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-07,1.3671729564666748,1.3671729564666748,1.2308690547943115,1.2308690547943115,9285,0.0,0.0,1.480347216129303,1.5686353147029877,,-16.852678791622118,-5.628338068520506,,33.08494255601241,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-08,1.296955943107605,1.61086905002594,1.296955943107605,1.3382600545883179,146996,0.0,0.0,1.4464776158332824,1.5556244403123856,,-7.481454262437574,-7.016270871726942,,40.44962210400451,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-09,1.3382600545883179,1.3382600545883179,1.276304006576538,1.3217389583587646,29168,0.0,0.0,1.4109559059143066,1.5357983618974687,,-6.323156321297578,-8.128831172141634,,39.72526543036643,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-12,1.3299989700317383,1.5695650577545166,1.280434012413025,1.4043469429016113,33029,0.0,0.0,1.398564600944519,1.5293961852788924,,0.4134483278918454,-8.554459962283465,,45.02630197921195,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-13,1.3754340410232544,1.3754340410232544,1.3217389583587646,1.3506519794464111,22328,0.0,0.0,1.3725428938865663,1.521961408853531,,-1.5949165987933265,-9.817496954769652,,42.41509020693312,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-14,1.342391014099121,1.342391014099121,1.1647820472717285,1.296955943107605,8249,0.0,0.0,1.3564341902732848,1.513184231519699,,-4.384897372256341,-10.358952861211707,,39.92176509486588,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-15,1.296955943107605,1.4043469429016113,1.2391300201416016,1.3713040351867676,9921,0.0,0.0,1.3489993929862976,1.51111900806427,,1.6534212184554018,-10.72844787292076,,44.76345842483041,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-16,1.3671729564666748,1.3671729564666748,1.1606520414352417,1.1730430126190186,18784,0.0,0.0,1.3258689999580384,1.501412484049797,,-11.526477151502641,-11.691889201444555,,36.35059506661423,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-19,1.3713040351867676,1.5241299867630005,1.2556519508361816,1.3299989700317383,53593,0.0,0.0,1.31926029920578,1.4934613823890686,,0.8139918128684034,-11.66425092991836,,45.14072704934194,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-20,1.3382600545883179,1.4373910427093506,1.3299989700317383,1.3299989700317383,5509,0.0,0.0,1.3147167921066285,1.4858200579881669,,1.1623931493734456,-11.515746133701812,,45.14072704934194,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-21,1.3299989700317383,1.3299989700317383,1.0945650339126587,1.3217389583587646,1740,0.0,0.0,1.3238037824630737,1.4773526817560196,,-0.15597659801721245,-10.393516808080905,,44.7634186109883,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-22,1.3217389583587646,1.3217389583587646,1.156520962715149,1.156520962715149,42672,0.0,0.0,1.3056298732757567,1.4643418043851852,,-11.420457942380056,-10.83844841649282,,37.93354361885096,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-23,1.1606520414352417,1.478695034980774,1.1606520414352417,1.2928260564804077,15164,0.0,0.0,1.3027385830879212,1.4573200821876526,,-0.7608991348070425,-10.60724414554706,,45.342825319297596,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-26,1.1978260278701782,1.2928260564804077,1.1606520414352417,1.276304006576538,17067,0.0,0.0,1.2899342894554138,1.451021182537079,,-1.0566649007082476,-11.101622431176931,,44.64708244376732,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-27,1.5199990272521973,1.5199990272521973,1.2308690547943115,1.2391300201416016,94825,0.0,0.0,1.2787820935249328,1.4447222828865052,,-3.1007685816143393,-11.485957635403093,,43.04664256502678,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-28,1.2928260564804077,1.2928260564804077,1.1647820472717285,1.2845649719238281,30999,0.0,0.0,1.2775429964065552,1.4379070818424224,,0.5496469032372424,-11.152604188470171,,45.612773494116766,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-29,1.2845649719238281,1.2845649719238281,1.0408689975738525,1.2639130353927612,187072,0.0,0.0,1.2668038964271546,1.4311951339244842,,-0.22820114798720414,-11.486290974631242,,44.62847477876921,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-30,1.2349989414215088,1.280434012413025,1.156520962715149,1.280434012413025,35559,0.0,0.0,1.2775429964065552,1.4249994844198226,,0.22629500647739204,-10.347827464183478,,45.639092170065176,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-03,1.280434012413025,1.280434012413025,1.1647820472717285,1.1730430126190186,15586,0.0,0.0,1.2618474006652831,1.416119059920311,,-7.037648767944862,-10.893975204578437,,40.46856391102892,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-04,1.210216999053955,1.210216999053955,1.1193469762802124,1.152390956878662,48007,0.0,0.0,1.2440865993499757,1.4058962345123291,,-7.370519264432534,-11.509358314661199,,39.540829258650966,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-05,1.1399990320205688,1.486956000328064,1.1399990320205688,1.3713040351867676,259969,0.0,0.0,1.2490431070327759,1.4016625344753266,,9.788367388250876,-10.888457363218286,,52.08107746643983,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-06,1.3713040351867676,1.4167389869689941,1.222607970237732,1.2721730470657349,43226,0.0,0.0,1.2606083154678345,1.3971190363168717,,0.9173929329197318,-9.7708725814023,,47.296982509326284,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-07,1.3836950063705444,1.3836950063705444,1.156520962715149,1.2308690547943115,56596,0.0,0.0,1.2544126152992248,1.3903038114309312,,-1.8768593537539653,-9.774208702761463,,45.42466771568226,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-10,1.222607970237732,1.222607970237732,1.1647820472717285,1.214347004890442,13269,0.0,0.0,1.2482169151306153,1.3829722851514816,,-2.7134634877647996,-9.74389519354006,,44.663026968874604,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-11,1.1978260278701782,1.1978260278701782,0.941739022731781,1.090433955192566,9260,0.0,0.0,1.2333473086357116,1.3725429326295853,,-11.58743789705365,-10.141440437655078,,39.335983682319416,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-12,1.090433955192566,1.2473909854888916,1.0821729898452759,1.1895649433135986,22163,0.0,0.0,1.2238473057746888,1.3636625051498412,,-2.8011960560218436,-10.252918067860882,,44.98881640722147,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-13,1.2515209913253784,1.2515209913253784,1.1895649433135986,1.1895649433135986,1680,0.0,0.0,1.2164124965667724,1.3538527280092238,,-2.207109293019339,-10.151785980780256,,44.98881640722147,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-14,1.1895649433135986,1.1895649433135986,1.0532599687576294,1.1482599973678589,6366,0.0,0.0,1.2031950950622559,1.3453853279352188,,-4.565768088636907,-10.56873669725418,,43.05028434453176,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-17,1.1482599973678589,1.2349989414215088,1.090433955192566,1.2349989414215088,10047,0.0,0.0,1.209390687942505,1.336608150601387,,2.1174508563953234,-9.517932581934534,,48.107057525276225,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-18,1.2597819566726685,1.3217389583587646,1.135869026184082,1.2184779644012451,18409,0.0,0.0,1.215999388694763,1.3232874989509582,,0.20383034148910972,-8.107694687756684,,47.24654295119019,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-19,1.1152169704437256,1.152390956878662,0.9913039803504944,1.1276079416275024,60683,0.0,0.0,1.1916297793388366,1.3112059712409974,,-5.372628212334206,-9.119558217767057,,42.72015429368999,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-20,0.9954339861869812,1.135869026184082,0.9913039803504944,1.135869026184082,107508,0.0,0.0,1.1779993772506714,1.2976787954568862,,-3.576432371714596,-9.22257638987452,,43.252422160507734,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-21,1.135869026184082,1.135869026184082,1.135869026184082,1.135869026184082,0,0.0,0.0,1.1684993743896483,1.2841516196727754,,-2.792500271778955,-9.006120734605876,,43.252422160507734,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-24,1.011955976486206,1.0945650339126587,1.003695011138916,1.0945650339126587,38391,0.0,0.0,1.1565211772918702,1.2733092457056046,,-5.3571127442983,-9.17201134034146,,41.04100475432154,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-25,1.0821729898452759,1.2639130353927612,1.0821729898452759,1.135869026184082,41357,0.0,0.0,1.1610646843910217,1.2614342451095581,,-2.1700477626838524,-7.956781029820474,,44.117933449207925,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-26,1.135869026184082,1.135869026184082,1.020216941833496,1.0656520128250122,23708,0.0,0.0,1.1486733913421632,1.251624470949173,,-7.227587854206751,-8.225396833998989,,40.27035226384463,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-27,1.2060860395431519,1.2060860395431519,0.9830430150032043,1.0449990034103394,146823,0.0,0.0,1.1342167973518371,1.2416081458330155,,-7.866026508318599,-8.649375315520965,,39.187799236356426,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-28,1.0491299629211426,1.0491299629211426,0.9499989748001099,1.0408689975738525,143390,0.0,0.0,1.1234776973724365,1.2325211971998216,,-7.352945233517967,-8.847190626426721,,38.96224048660156,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-31,1.1317390203475952,1.1317390203475952,1.020216941833496,1.0284780263900757,9563,0.0,0.0,1.1028256058692931,1.2233309984207152,,-6.741553613149341,-9.850595849119419,,38.25088022175949,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-01,1.069782018661499,1.1399990320205688,0.9747819900512695,1.1317390203475952,45491,0.0,0.0,1.0941517114639283,1.217238622903824,,3.435292244196803,-10.111978795600614,,46.94434670570918,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-02,1.1234780550003052,1.1234780550003052,0.9747819900512695,0.9995650053024292,9758,0.0,0.0,1.0813474178314209,1.2114560216665269,,-7.563009924507104,-10.739853656109075,,39.31459383642429,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-03,1.0821729898452759,1.0821729898452759,0.8797820210456848,0.9747819900512695,65091,0.0,0.0,1.0652387142181396,1.2023690700531007,,-8.491685756395292,-11.405013589455098,,38.06534295838213,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-04,1.024346947669983,1.024346947669983,0.9871730208396912,0.9871730208396912,762,0.0,0.0,1.0503691136837006,1.1940049216151238,,-6.016560466289544,-12.029750073151115,,39.10718032581025,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-07,0.9913039803504944,0.9913039803504944,0.9169560074806213,0.9169560074806213,9557,0.0,0.0,1.0326082110404968,1.181820148229599,,-11.200008127316725,-12.625604446888634,,35.46633594150293,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-08,0.9169560074806213,0.9458690285682678,0.8797820210456848,0.9334779977798462,47890,0.0,0.0,1.0123691082000732,1.1713907986879348,,-7.792722020181977,-13.575460099736187,,36.95367533310355,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-09,0.9334779977798462,0.9995650053024292,0.87152099609375,0.9789130091667175,4803,0.0,0.0,1.0036952078342438,1.1634397253394126,,-2.4690960437084173,-13.730364713012206,,40.98197169722211,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-10,0.9789130091667175,1.020216941833496,0.8797820210456848,0.9706519842147827,36553,0.0,0.0,0.9962605059146881,1.1534234240651131,,-2.5704644064349034,-13.625778258995446,,40.47558446744329,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-11,1.0449990034103394,1.0449990034103394,0.9169560074806213,0.9747819900512695,84279,0.0,0.0,0.9896518051624298,1.1484668985009194,,-1.5025299841412103,-13.828443252982664,,40.86895953602972,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-14,0.9913039803504944,1.0532599687576294,0.9210860133171082,0.9913039803504944,97558,0.0,0.0,0.9859344005584717,1.1399995237588882,,0.5446183629439386,-13.514490137015317,,42.50589438694687,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-15,0.937608003616333,1.0532599687576294,0.9045649766921997,0.9045649766921997,66658,0.0,0.0,0.9632169961929321,1.1293636739253998,,-6.0891802919333475,-14.711530180086395,,36.75346938654748,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-16,0.9169560074806213,0.9995650053024292,0.9169560074806213,0.9954339861869812,51616,0.0,0.0,0.9628038942813874,1.1212060496211051,,3.389069373254678,-14.127836305668119,,45.13098119238919,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-17,0.9954339861869812,0.9954339861869812,0.9499989748001099,0.9913039803504944,16896,0.0,0.0,0.9644560933113098,1.1170756250619889,,2.783733466497845,-13.662417147649242,,44.840267098637746,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-18,0.9789130091667175,1.0160859823226929,0.875652015209198,0.9128260016441345,41678,0.0,0.0,0.9570213913917541,1.107575623691082,,-4.61801482653885,-13.59313342393671,,39.61792982620435,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-21,0.9045649766921997,1.0656520128250122,0.8467389941215515,1.0573910474777222,33452,0.0,0.0,0.9710648953914642,1.1021027997136117,,8.889843768006605,-11.88980777076317,,50.95056498783866,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-22,0.9582599997520447,1.0367389917373657,0.9252169728279114,0.9293469786643982,37750,0.0,0.0,0.9706517934799195,1.0943582236766816,,-4.255368927660235,-11.304016136612875,,43.21430142536068,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-23,0.9582599997520447,1.0491299629211426,0.8591300249099731,1.0491299629211426,48733,0.0,0.0,0.977673488855362,1.0884723484516143,,7.308828037204959,-10.179299433179645,,50.74827428121651,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-24,1.0408689975738525,1.0408689975738525,0.7946950197219849,1.003695011138916,18074,0.0,0.0,0.9809777915477753,1.0819668978452683,,2.31577307731888,-9.333844362393371,,48.13933033156979,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-25,0.9830430150032043,1.0326080322265625,0.9128260016441345,1.0326080322265625,48860,0.0,0.0,0.9867603957653046,1.0757712483406068,,4.646278535094601,-8.27414310547923,,49.9042794233888,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-28,1.0491299629211426,1.0491299629211426,0.8260859847068787,0.9913039803504944,64552,0.0,0.0,0.9867603957653046,1.0712277725338937,,0.4604546964682235,-7.885099596399468,,47.42141807663466,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-29,0.9747819900512695,0.9747819900512695,0.8673909902572632,0.9747819900512695,53062,0.0,0.0,0.9937820971012116,1.0667875483632088,,-1.9118987054973053,-6.843485506932545,,46.42639303490822,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-30,0.9706519842147827,0.9706519842147827,0.8343470096588135,0.9334779977798462,37097,0.0,0.0,0.987586498260498,1.0558418974280357,,-5.478861909914399,-6.46454732794782,,43.943984487670974,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-01,0.9293469786643982,0.9789130091667175,0.8343470096588135,0.883912980556488,130054,0.0,0.0,0.9768473982810975,1.0461353957653046,,-9.513708885148366,-6.623234216591935,,41.10372872965581,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-02,0.8549990057945251,0.9458690285682678,0.8426079750061035,0.9293469786643982,11932,0.0,0.0,0.9784994959831238,1.0385973438620568,,-5.023254229614171,-5.786443440675217,,44.63616671336316,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-05,0.8921729922294617,0.9665210247039795,0.875652015209198,0.9582599997520447,11805,0.0,0.0,0.968586391210556,1.0321951687335968,,-1.0661301410197626,-6.162475803978295,,46.82199473412739,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-06,0.8797820210456848,0.9334779977798462,0.8797820210456848,0.9128260016441345,16786,0.0,0.0,0.9669342935085297,1.027754969894886,,-5.595860259342206,-5.917818757186531,,43.889592438701975,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-07,0.9128260016441345,0.9128260016441345,0.87152099609375,0.875652015209198,12827,0.0,0.0,0.9495864987373352,1.019907146692276,,-7.785966168058192,-6.894808824803513,,41.594238408392044,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-08,0.875652015209198,0.9210860133171082,0.8591300249099731,0.8673909902572632,32016,0.0,0.0,0.9359560966491699,1.0118527978658676,,-7.325675492405857,-7.500765069462073,,41.08007771876458,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-09,0.875652015209198,0.9499989748001099,0.875652015209198,0.9086949825286865,22152,0.0,0.0,0.9235647916793823,1.0058636724948884,1.340566516915957,-1.610045043364742,-8.181912029030384,-24.967268703015943,44.75701014233504,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-12,0.9045649766921997,0.9045649766921997,0.8260859847068787,0.8632599711418152,90747,0.0,0.0,0.9107603907585144,0.9965701982378959,1.3323400671283403,-5.2154683162208215,-8.61051310094439,-25.201514025930788,41.676002125950966,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-13,0.9086949825286865,0.9086949825286865,0.712086021900177,0.8260859847068787,47158,0.0,0.0,0.8958907902240754,0.9867603987455368,1.3216697762409846,-7.791664595607406,-9.208882788261818,-25.33986806053607,39.29271184055131,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-14,0.8549990057945251,0.9541299939155579,0.7831299901008606,0.9252169728279114,46579,0.0,0.0,0.8950646877288818,0.9817006245255471,1.313684267302354,3.3687269213510516,-8.825087265125878,-25.271189664053317,47.85616357697831,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-15,0.9293469786643982,0.9293469786643982,0.7666079998016357,0.77817302942276,49144,0.0,0.0,0.884490692615509,0.972758224606514,1.305024117231369,-12.02021277107612,-9.07394353069691,-25.460517414020124,39.055546417887754,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-16,0.8426079750061035,0.8426079750061035,0.7699130177497864,0.8145210146903992,89187,0.0,0.0,0.8730080962181092,0.9647245243191719,1.2974241172273955,-6.699489017464712,-9.507007004490646,-25.64308682801465,41.89981528462437,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-19,0.8128690123558044,0.8128690123558044,0.7682600021362305,0.7847819924354553,36246,0.0,0.0,0.8556602954864502,0.9569799482822419,1.2895762920379639,-8.283462891158218,-10.587437383370284,-25.791133553650248,40.244890588449394,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-20,0.8227819800376892,0.8260859847068787,0.7748690247535706,0.7748690247535706,2085,0.0,0.0,0.8418645977973938,0.9479549482464791,1.2812328174710275,-7.95799861629846,-11.19149709016558,-26.012280100847857,39.68225888238932,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-21,0.7847819924354553,0.7847819924354553,0.7533910274505615,0.7847819924354553,9139,0.0,0.0,0.8327775955200195,0.9409331977367401,1.2730407843987146,-5.763315841199333,-11.494503805038562,-26.087741314496554,40.57690930445743,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-22,0.7847819924354553,0.7847819924354553,0.6608690023422241,0.7269560098648071,321916,0.0,0.0,0.818734097480774,0.9329821228981018,1.2634719431400299,-11.209755144969034,-12.24546779765101,-26.15727417108938,37.11830809886827,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-23,0.7219989895820618,0.7219989895820618,0.6195650100708008,0.6707820296287537,23266,0.0,0.0,0.7949428021907806,0.9237299486994743,1.253503826757272,-15.618830967442266,-13.942077626693173,-26.308166837503798,34.07944653063211,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-27,0.7385209798812866,0.7385209798812866,0.6641730070114136,0.690608024597168,42796,0.0,0.0,0.7776776075363159,0.9152831986546517,1.2441828106840451,-11.196102613136118,-15.03420922842223,-26.434990839374013,36.06883608603033,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-28,0.690608024597168,0.7566949725151062,0.690608024597168,0.7451300024986267,23060,0.0,0.0,0.7695820093154907,0.9056179732084274,1.2353161444266638,-3.1773100879285074,-15.021340997792688,-26.689376052092012,41.313952630043936,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-29,0.7286080121994019,0.7286080121994019,0.6691300272941589,0.712086021900177,10067,0.0,0.0,0.7482689142227172,0.8984309986233712,1.2261741116642952,-4.835546637685211,-16.713813818839856,-26.7289212782413,39.2140935463992,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-30,0.6856520175933838,0.7831299901008606,0.6526079773902893,0.6526079773902893,43857,0.0,0.0,0.7357124090194702,0.8903766483068466,1.216123386224111,-11.295776802234363,-17.370653147910854,-26.78566513951034,35.6970721714077,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-02,0.6724339723587036,0.6873040199279785,0.6443470120429993,0.6608690023422241,73794,0.0,0.0,0.7203472077846527,0.88221904784441,1.2040074437856674,-8.256880126647136,-18.348259477651332,-26.72644572108982,36.54828493742589,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-03,0.6608690023422241,0.743478000164032,0.6493039727210999,0.7170429825782776,40167,0.0,0.0,0.7135733067989349,0.8772212222218514,1.1961458519101142,0.48623957010212393,-18.655261783159357,-26.662687428876257,42.15559634073233,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-04,0.743478000164032,0.7814779877662659,0.7170429825782776,0.7798259854316711,7829,0.0,0.0,0.714069002866745,0.873379921913147,1.1889107098182043,9.208771463392772,-18.240735222929086,-26.539485707324907,47.716756493617666,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-05,0.7765210270881653,0.8302170038223267,0.7765210270881653,0.8302170038223267,40229,0.0,0.0,0.7186125040054321,0.8696625217795372,1.1820954928795497,15.530553559091834,-17.368808473546807,-26.43043417236412,51.728136912771696,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-09,0.8302170038223267,0.9499989748001099,0.7253040075302124,0.9086949825286865,187292,0.0,0.0,0.73678640127182,0.8681135967373848,1.177552009622256,23.332214188552165,-15.12788141541951,-26.278110041537378,57.23157339207648,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-10,0.8467389941215515,0.8921729922294617,0.8260859847068787,0.8921729922294617,89143,0.0,0.0,0.7589254975318909,0.8660483717918396,1.1719759181141853,17.557388061266398,-12.369156013573846,-26.103569330555075,55.789486275446926,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-11,0.8921729922294617,0.8921729922294617,0.7880859971046448,0.8797820210456848,11475,0.0,0.0,0.7778428971767426,0.8632603228092194,1.1655737429857254,13.105361537521304,-9.89474708561974,-25.936876323423526,54.6767652555437,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-12,0.8591300249099731,0.8880429863929749,0.7666079998016357,0.8880429863929749,75097,0.0,0.0,0.7921341955661774,0.8628472730517387,1.1593436683217684,12.107644306183088,-8.195317954179961,-25.574504210578823,55.31663262146147,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-13,0.8963040113449097,0.9458690285682678,0.8797820210456848,0.9086949825286865,27411,0.0,0.0,0.8117950916290283,0.8606787979602813,1.1530791764458022,11.936496278292262,-5.679668936553604,-25.3582220942366,56.95280783817052,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-16,0.937608003616333,0.937608003616333,0.7616519927978516,0.8227819800376892,214238,0.0,0.0,0.8288124918937683,0.8564657479524612,1.1459610591332117,-0.7276087070429929,-3.2287638034332544,-25.262229364034454,48.92659847284973,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-17,0.8963040113449097,0.8963040113449097,0.8227819800376892,0.8302170038223267,122533,0.0,0.0,0.8457472920417786,0.854400523006916,1.13976540962855,-1.8362799816904092,-1.0127839031141883,-25.037159770854473,49.58871023269679,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-18,0.8302170038223267,0.9086949825286865,0.8302170038223267,0.8591300249099731,69820,0.0,0.0,0.8599559962749481,0.8494439974427224,1.134189326564471,-0.09604809647851949,1.2375152292408276,-25.105625882079107,52.18467857553641,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-19,0.8302170038223267,1.1978260278701782,0.7765210270881653,0.8244339823722839,228985,0.0,0.0,0.8644167959690094,0.8468211725354194,1.1286338930328688,-4.62540915252634,2.077844060146482,-24.969365374998727,48.928525149514606,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-20,0.9045649766921997,0.9871730208396912,0.7996519804000854,0.8508689999580383,163424,0.0,0.0,0.8664819955825805,0.8418646484613419,1.1227480262517928,-1.8018834441037395,2.9241454865970726,-25.017490231370815,51.41589518264804,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-23,0.8508689999580383,0.9871730208396912,0.7930430173873901,0.9830430150032043,212811,0.0,0.0,0.8739167988300324,0.841348348557949,1.1181701267759006,12.487025803745407,3.87098284888832,-24.756678039336595,61.50987592214427,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-24,0.9871730208396912,1.0326080322265625,0.9252169728279114,1.0160859823226929,119727,0.0,0.0,0.8863080978393555,0.8409352973103523,1.113902010023594,14.64252496391608,5.395516239373414,-24.505451130971544,63.54878525570264,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-25,1.0160859823226929,1.0160859823226929,0.8797820210456848,0.9499989748001099,54474,0.0,0.0,0.893329793214798,0.8399026721715928,1.109083168208599,6.3435902413349785,6.3611085919119486,-24.27054198936127,57.04067383250782,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-26,0.9665210247039795,1.0160859823226929,0.8880429863929749,0.9293469786643982,68606,0.0,0.0,0.8974601924419403,0.8387667968869209,1.1038168599208196,3.5530028508223497,6.997582137592913,-24.012141203651442,55.14026429561915,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-27,0.9582599997520447,1.024346947669983,0.9169560074806213,0.9747819900512695,109986,0.0,0.0,0.9040688931941986,0.8397993966937065,1.0991012761990229,7.821649145258382,7.65295816519056,-23.592173453027865,58.42225099421243,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-30,0.9913039803504944,1.0573910474777222,0.9871730208396912,0.9913039803504944,12430,0.0,0.0,0.9209210932254791,0.8424841716885567,1.0952462012569109,7.642662074174327,9.31019527402093,-23.078101460501117,59.58030689212219,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-31,0.9913039803504944,1.0449990034103394,0.9747819900512695,1.0326080322265625,21733,0.0,0.0,0.9411601960659027,0.8450656980276108,1.0913222844401995,9.7165006066891,11.37124584071714,-22.564973695090224,62.39981597555635,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-01,1.222607970237732,1.222607970237732,1.0449990034103394,1.0821729898452759,122901,0.0,0.0,0.963464492559433,0.8481635227799416,1.0877769922216733,12.321003856664715,13.59419105900486,-22.027811872757646,65.5090434084633,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-02,1.0986950397491455,1.2349989414215088,1.0986950397491455,1.156520962715149,71369,0.0,0.0,0.9966731905937195,0.8542558968067169,1.0848512664437293,16.038133023946184,16.671502569589617,-21.255943258741016,69.57342656019054,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-03,1.1813039779663086,1.1813039779663086,1.135869026184082,1.135869026184082,108166,0.0,0.0,1.025173193216324,0.860761322081089,1.081443657974402,10.797768972135026,19.10075033782086,-20.406272140581233,67.20443417328073,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-06,1.135869026184082,1.135869026184082,1.0078259706497192,1.078042984008789,26954,0.0,0.0,1.0346731901168824,0.8660276219248771,1.0772443825999896,4.191641796286164,19.47346296151213,-19.60713502773892,60.946690500216306,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-07,1.152390956878662,1.152390956878662,1.0739129781723022,1.1152169704437256,8721,0.0,0.0,1.0445862889289856,0.8711906716227531,1.0741465573509534,6.76159377768184,19.9032913177607,-18.894617716666854,63.31177618047727,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-08,1.1152169704437256,1.1152169704437256,0.9995650053024292,1.061521053314209,21468,0.0,0.0,1.0557384967803956,0.876147198677063,1.0697751825054487,0.5477262173775087,20.49784538197532,-18.09987621650584,57.8609606229627,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-09,1.0573910474777222,1.1399990320205688,0.9582599997520447,1.0408689975738525,75912,0.0,0.0,1.066890698671341,0.8815167739987373,1.0638548905650775,-2.43902221004407,21.02897303152953,-17.139378517072895,55.868672930491094,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-10,0.9954339861869812,1.144129991531372,0.8963040113449097,1.0532599687576294,33101,0.0,0.0,1.0747384965419768,0.8847178488969802,1.0592081482211748,-1.998488735023045,21.478107159463818,-16.473655307243636,56.82914297521821,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-13,1.0491299629211426,1.0491299629211426,1.0367389917373657,1.0367389917373657,2861,0.0,0.0,1.079281997680664,0.8911819979548454,1.053873006006082,-3.941787784353079,21.106799751059295,-15.437439532472244,55.10704050811462,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-14,1.0326080322265625,1.0326080322265625,0.9458690285682678,0.9499989748001099,19715,0.0,0.0,1.0710210919380188,0.8945689469575882,1.0478150303165117,-11.299695033915595,19.72482340020196,-14.62529921074264,47.04619107297699,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-15,0.9499989748001099,1.135869026184082,0.8260859847068787,0.9045649766921997,155966,0.0,0.0,1.053260290622711,0.8975635215640068,1.0426175718506177,-14.117622704887067,17.346601696490772,-13.91248854833167,43.460181892028245,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-16,0.9665210247039795,1.069782018661499,0.6509559750556946,0.8426079750061035,135923,0.0,0.0,1.0218689918518067,0.8992569953203201,1.0362153962254523,-17.54246564629098,13.634811535473409,-13.217174865768333,39.08504482207723,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-17,0.8426079750061035,0.937608003616333,0.743478000164032,0.8260859847068787,90112,0.0,0.0,0.9908906877040863,0.9002895951271057,1.030949087937673,-16.63197616470324,10.063549891875539,-12.673709530306745,37.98682378195736,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-20,0.8549990057945251,0.8549990057945251,0.7963470220565796,0.8227819800376892,56163,0.0,0.0,0.9653645873069763,0.9026852443814277,1.0257585043708484,-14.769819521455807,6.9436543153533075,-11.99826854615336,37.758340192204436,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-21,0.8227819800376892,0.8227819800376892,0.7682600021362305,0.7847819924354553,42680,0.0,0.0,0.9323210895061493,0.9055352434515953,1.0205954631169638,-15.824923272822833,2.958012539904621,-11.273832171854579,35.14041965068874,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-22,0.8549990057945251,0.8632599711418152,0.6757389903068542,0.7831299901008606,57894,0.0,0.0,0.9044819831848144,0.9078482925891876,1.0154874965548515,-13.416739674200647,-0.37080087409455637,-10.599756701174677,35.026721098306766,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-23,0.9706519842147827,0.9706519842147827,0.6839990019798279,0.7765210270881653,85753,0.0,0.0,0.8780471861362458,0.9086330682039261,1.010496554772059,-11.562722442609909,-3.366142300779204,-10.080537740290525,34.54516967613213,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-24,0.7715650200843811,0.7715650200843811,0.7352169752120972,0.7352169752120972,10020,0.0,0.0,0.8462428867816925,0.909211342036724,1.0063661207755408,-13.119863493545317,-6.925612598933925,-9.654019221547907,31.619395712627124,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-27,0.7352169752120972,0.7500860095024109,0.6823469996452332,0.7104340195655823,118428,0.0,0.0,0.8136123895645142,0.9106569930911064,1.001134237150351,-12.68151411191736,-10.65654843292719,-9.037473767432127,29.978759747002414,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-28,0.6195650100708008,0.6195650100708008,0.4956519901752472,0.545216977596283,401687,0.0,0.0,0.7731341898441315,0.9077656924724579,0.9946632206439971,-29.479644703566667,-14.83108512964772,-8.736376933217382,21.84219113077404,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-01,0.545216977596283,0.545216977596283,0.4774779975414276,0.5369560122489929,45011,0.0,0.0,0.7363732933998108,0.9032635182142258,0.9874349628885587,-27.08100401497656,-18.47636060231471,-8.52425201028986,21.527573289072023,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-02,0.5022600293159485,0.6476519703865051,0.49234700202941895,0.6146079897880554,48883,0.0,0.0,0.713573294878006,0.8991330683231353,0.9813012629747391,-13.868975450779716,-20.63763195710224,-8.373391307223757,31.513703593926195,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-03,0.6013910174369812,0.6013910174369812,0.5468689799308777,0.5749559998512268,32265,0.0,0.0,0.6884602963924408,0.8927515432238579,0.9752845967809359,-16.48668734217223,-22.883326092463662,-8.462458427979898,29.452595056051223,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-06,0.5815650224685669,0.5815650224685669,0.5567820072174072,0.5567820072174072,19489,0.0,0.0,0.6618602991104126,0.8839537188410759,0.9684969132145246,-15.876204092349708,-25.125005415650385,-8.729319961675724,28.53151723035576,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-07,0.5617390275001526,0.6013910174369812,0.5600860118865967,0.5683469772338867,30437,0.0,0.0,0.6402167975902557,0.8758580684661865,0.9634577795863152,-11.225856713988676,-26.904047511783354,-9.092221057962892,30.03105339158344,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-08,0.5369560122489929,0.5617390275001526,0.5369560122489929,0.5617390275001526,9123,0.0,0.0,0.6180777013301849,0.8679069936275482,0.9570556133985519,-9.115144213872147,-28.78526087837639,-9.314883954803063,29.648273868169753,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-09,0.5617390275001526,0.6096519827842712,0.5600860118865967,0.5716519951820374,27800,0.0,0.0,0.5975907981395722,0.8599972188472748,0.9507360552748044,-4.3405626455909045,-30.512473175137423,-9.544061774464014,31.06773121521522,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-10,0.5716519951820374,0.5716519951820374,0.545216977596283,0.545216977596283,6611,0.0,0.0,0.5785907983779908,0.8509102687239647,0.9442650387684505,-5.7681215939256685,-32.00331225927588,-9.886500739902743,29.366140680451252,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-13,0.5947819948196411,0.5947819948196411,0.5815650224685669,0.5815650224685669,26316,0.0,0.0,0.5657038986682892,0.8448798447847367,0.9394737392663955,2.803785485236362,-33.043272110199,-10.068817309946757,34.664945412318616,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-14,0.5832170248031616,0.5848690271377563,0.545216977596283,0.5848690271377563,25781,0.0,0.0,0.5696691036224365,0.8387461453676224,0.9335740973552068,2.6682021929337427,-32.080867760918224,-10.157517465001414,35.1412424545632,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-15,0.6146079897880554,0.7104340195655823,0.5799130201339722,0.5832170248031616,127601,0.0,0.0,0.5742952048778533,0.831848320364952,0.9277983725070953,1.553525059852424,-30.96154781848978,-10.341692223803667,35.00383763230114,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-16,0.6261730194091797,0.6757389903068542,0.5782600045204163,0.6658260226249695,60515,0.0,0.0,0.5794170081615448,0.8278831213712692,0.9230208391944568,14.913095964786264,-30.012221145199337,-10.307212338371109,46.309235057750236,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-17,0.6658260226249695,0.743478000164032,0.5997390151023865,0.7253040075302124,46514,0.0,0.0,0.5944518089294434,0.8247439965605736,0.9183603311578433,22.012246684289273,-27.92286922869603,-10.193856531154912,52.68989509946884,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-20,0.7253040075302124,1.0078259706497192,0.7038260102272034,0.8260859847068787,6902,0.0,0.0,0.6213822066783905,0.8208200708031654,0.9147117724021275,32.9432957410763,-24.29739125769996,-10.26462153781981,61.12112634073373,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-21,0.8260859847068787,0.9499989748001099,0.8029559850692749,0.9086949825286865,81703,0.0,0.0,0.6554170072078704,0.8181352958083152,0.9116139471530914,38.6437905235021,-19.88892172653175,-10.254192757439009,66.4059301907367,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-22,0.9086949825286865,0.9086949825286865,0.7715650200843811,0.8632599711418152,35041,0.0,0.0,0.6855691015720368,0.8159668207168579,0.909032421807448,25.9187395059559,-15.98076243225941,-10.2378747839979,61.45780990088879,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-23,0.9913039803504944,0.9913039803504944,0.8260859847068787,0.9458690285682678,51316,0.0,0.0,0.7229908049106598,0.8163798719644546,0.9073114057381948,30.827255636418382,-11.439413226721614,-10.02208648526331,66.36513452971839,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-24,0.875652015209198,0.941739022731781,0.817825973033905,0.9293469786643982,12392,0.0,0.0,0.7614038050174713,0.8152439966797829,0.903628430267175,22.057044178164205,-6.604181310329758,-9.781059407488936,64.59372222583792,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-27,0.9706519842147827,0.9706519842147827,0.7748690247535706,0.87152099609375,66848,0.0,0.0,0.7903994023799896,0.8122494220733643,0.9002896631757419,10.263367288676244,-2.690062818093466,-9.779101627338317,58.689238535313144,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-28,0.8549990057945251,0.8591300249099731,0.6509559750556946,0.6625210046768188,199228,0.0,0.0,0.7981646001338959,0.8029972463846207,0.8955534294247627,-16.994438920784283,-0.6018260053173362,-10.335082195999547,43.287701288774265,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-29,0.6493039727210999,0.6493039727210999,0.5716519951820374,0.617913007736206,69848,0.0,0.0,0.8016341984272003,0.7913907468318939,0.8905831461151441,-22.918332457803537,1.2943607991770307,-11.137915613600164,40.82515407682136,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-30,0.611303985118866,0.6377390027046204,0.5303469896316528,0.5319989919662476,69145,0.0,0.0,0.7882514953613281,0.7757776975631714,0.8859295214215914,-32.50897776953997,1.6079087910542795,-12.433474807529478,36.51646859578903,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-31,0.7239999771118164,0.7239999771118164,0.5600000023841858,0.656000018119812,125921,0.0,0.0,0.7813210964202881,0.7637809723615646,0.8814831470449765,-16.03963836054715,2.2964861253993423,-13.352742486114295,45.46299040349368,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-03,0.6579999923706055,0.6840000152587891,0.6480000019073486,0.6480000019073486,60955,0.0,0.0,0.7635124981403351,0.7530298978090286,0.8769701058665912,-15.129090422794233,1.3920563262900971,-14.132774564201272,45.022161802934015,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-04,0.671999990940094,0.6959999799728394,0.6000000238418579,0.6000000238418579,51894,0.0,0.0,0.7326430022716522,0.7401494741439819,0.8724012727538745,-18.104721947594943,-1.0141832338678967,-15.159514633950334,42.36767108161268,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-05,0.6639999747276306,0.6639999747276306,0.5120000243186951,0.593999981880188,126701,0.0,0.0,0.7057170033454895,0.7284614473581315,0.8670596147576968,-15.830286210435759,-3.1222577522980686,-15.98484868174804,42.03404958099667,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-06,0.5600000023841858,0.5600000023841858,0.5400000214576721,0.5460000038146973,45745,0.0,0.0,0.6657301008701324,0.7160897225141525,0.8614556317528089,-17.984780453661887,-7.032585451332853,-16.87445108959118,39.36359250546604,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-11,0.5400000214576721,0.5960000157356262,0.5199999809265137,0.5600000023841858,136427,0.0,0.0,0.6287954032421113,0.7037582233548164,0.856725565592448,-10.940824392673955,-10.651786028923016,-17.85488240120985,40.54993031837903,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-12,0.5600000023841858,0.5899999737739563,0.527999997138977,0.5440000295639038,203076,0.0,0.0,0.5960433065891266,0.6914397493004799,0.8517933239539465,-8.731459014789014,-13.796783133724166,-18.825408716414913,39.59645993526823,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-13,0.5440000295639038,0.6700000166893005,0.48500001430511475,0.5379999876022339,358965,0.0,0.0,0.583591204881668,0.681139774620533,0.8468110819657644,-7.812183750897765,-14.321373288354778,-19.564140204760484,39.223992236605206,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-14,0.5379999876022339,0.5580000281333923,0.5,0.5540000200271606,178194,0.0,0.0,0.5771999061107635,0.672375650703907,0.8423063735167186,-4.019384937174763,-14.155144448420229,-20.174455299837362,40.822590955169666,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-17,0.5519999861717224,0.5519999861717224,0.5120000243186951,0.5120000243186951,76787,0.0,0.0,0.5752000093460083,0.6641104519367218,0.8371074651678403,-10.987479833174982,-13.387899909032763,-20.666045929530988,37.997239950446385,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-18,0.5479999780654907,0.5479999780654907,0.5099999904632568,0.5199999809265137,80981,0.0,0.0,0.5616000056266784,0.6564583018422127,0.8325603649020195,-7.4074117313699315,-14.450010906912789,-21.151867237942742,38.865167826728744,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-19,0.5460000038146973,0.5460000038146973,0.49300000071525574,0.5120000243186951,19492,0.0,0.0,0.5480000078678131,0.6486887529492378,0.8281187067429224,-6.569339969389534,-15.521888521058408,-21.667177945949494,38.28797660939907,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-20,0.5,0.5139999985694885,0.5,0.5099999904632568,98963,0.0,0.0,0.539000004529953,0.6418192028999329,0.8236947983503342,-5.380336516320863,-16.01996292809746,-22.08045939037798,38.13549308126322,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-21,0.5099999904632568,0.527999997138977,0.5099999904632568,0.5239999890327454,7182,0.0,0.0,0.5320000052452087,0.63534095287323,0.8194908147056897,-1.503762431125545,-16.265431523133838,-22.471253921082074,39.938639562206546,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-24,0.5299999713897705,0.5540000200271606,0.5,0.5440000295639038,34303,0.0,0.0,0.5318000078201294,0.6295279279351235,0.8145929897824923,2.2940995796112977,-15.524000727901866,-22.718715256410906,42.516277441939536,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-25,0.5559999942779541,0.5559999942779541,0.5400000214576721,0.5400000214576721,80908,0.0,0.0,0.529800009727478,0.6246475040912628,0.810763281583786,1.9252569918677211,-15.18416286666653,-22.955624868575107,42.126873229672896,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-26,0.5540000200271606,0.5540000200271606,0.4860000014305115,0.49399998784065247,104616,0.0,0.0,0.5248000055551529,0.6192366532981396,0.8067567648986975,-5.868905752376864,-15.250493852391338,-23.243698690782516,37.83522875081036,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-27,0.5400000214576721,0.5400000214576721,0.49000000953674316,0.515999972820282,41723,0.0,0.0,0.5226000040769577,0.6185062281787396,0.8028303228318692,-1.2629221594311022,-15.506104826816117,-22.95928409915469,40.93441678815119,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-28,0.5540000200271606,0.5540000200271606,0.460999995470047,0.515999972820282,173995,0.0,0.0,0.5187999993562699,0.6179823271930218,0.799489022543033,-0.5397121317390451,-16.04937932242408,-22.702837716604353,40.93441678815118,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-02,0.5099999904632568,0.5099999904632568,0.5099999904632568,0.5099999904632568,18080,0.0,0.0,0.518599995970726,0.6153671272099018,0.795960039148728,-1.658311911740673,-15.725105706884552,-22.68869077045233,40.298947960397946,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-03,0.5299999713897705,0.5299999713897705,0.46299999952316284,0.46299999952316284,3020,0.0,0.0,0.512899997830391,0.6125682272017002,0.791660764068365,-9.728991717354107,-16.270551580288135,-22.6223838536981,35.63251904455224,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-04,0.5059999823570251,0.5059999823570251,0.46299999952316284,0.48500001430511475,77510,0.0,0.0,0.5101999968290329,0.6107736773788929,0.7876136643191178,-4.939236119274745,-16.46660363319311,-22.452630642600763,39.182526014544614,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-05,0.49000000953674316,0.5120000243186951,0.46299999952316284,0.5099999904632568,39785,0.0,0.0,0.5101999968290329,0.6093150027096271,0.7837404809892178,-0.03920156154825069,-16.26662817095086,-22.255514741236173,43.027797496590786,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-08,0.5099999904632568,0.5099999904632568,0.453000009059906,0.453000009059906,44557,0.0,0.0,0.5030999988317489,0.606596527248621,0.7792546145617962,-9.958256785565569,-17.061839916279766,-22.156825777703897,37.24559440596398,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-09,0.453000009059906,0.46700000762939453,0.44999998807907104,0.46700000762939453,31964,0.0,0.0,0.49539999663829803,0.603980227559805,0.7756082398196061,-5.732739039487506,-17.97744793073636,-22.12818320492818,39.39965196767192,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-10,0.46700000762939453,0.4699999988079071,0.44999998807907104,0.4699999988079071,7999,0.0,0.0,0.48839999437332154,0.6020998030900955,0.7712296232581138,-3.767402902824342,-18.883880734264316,-21.92989157412257,39.875905601043556,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-11,0.4699999988079071,0.4699999988079071,0.44999998807907104,0.4699999988079071,1602,0.0,0.0,0.485999995470047,0.599310677498579,0.7668854234119257,-3.292180413842415,-18.90683518295912,-21.851340604153766,39.87590560104356,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-12,0.46000000834465027,0.4690000116825104,0.39100000262260437,0.4690000116825104,69975,0.0,0.0,0.4812999993562698,0.5964139521121978,0.7631868734955788,-2.5555760835675176,-19.30101607252016,-21.852173717234024,39.75512419090458,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-15,0.421999990940094,0.5019999742507935,0.421999990940094,0.43299999833106995,22825,0.0,0.0,0.47300000190734864,0.5926585264503956,0.75798361475269,-8.456660341433551,-20.190129594476048,-21.8111691446306,35.577254383178044,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-16,0.49300000071525574,0.49300000071525574,0.41100001335144043,0.46700000762939453,27420,0.0,0.0,0.4687000036239624,0.5876878760755062,0.7541307233273983,-0.3627044978501403,-20.24678018647031,-22.070821689574977,41.798236966545026,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-17,0.40700000524520874,0.43700000643730164,0.4000000059604645,0.43700000643730164,23374,0.0,0.0,0.4661000043153763,0.5804802760481834,0.7490296403566996,-6.2432949171107035,-19.704420021208932,-22.502362420297594,38.285237968629175,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-19,0.4339999854564667,0.4350000023841858,0.35499998927116394,0.3840000033378601,510171,0.0,0.0,0.4560000032186508,0.569428126513958,0.7438655152916909,-15.789473546619009,-19.919655881720278,-23.450124409831123,33.00724669746451,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-22,0.3889999985694885,0.39899998903274536,0.36000001430511475,0.38999998569488525,203232,0.0,0.0,0.44400000274181367,0.5564607515931129,0.7385104482372602,-12.162165926455966,-20.210005562715978,-24.650930407102436,34.11459764336598,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-23,0.3799999952316284,0.39899998903274536,0.3400000035762787,0.36800000071525574,324568,0.0,0.0,0.4355000019073486,0.5440792523324489,0.7333162484069665,-15.499426153034394,-19.956513680612673,-25.805646129566906,32.024362969400414,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-24,0.367000013589859,0.367000013589859,0.3409999907016754,0.36000001430511475,219666,0.0,0.0,0.4248000025749207,0.5294325269758702,0.7281930652757486,-15.254234434327094,-19.76314621215525,-27.295033113864207,31.273968985124043,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-25,0.36000001430511475,0.39899998903274536,0.3019999861717224,0.35899999737739563,232574,0.0,0.0,0.4137000024318695,0.5151738524436951,0.7234057486057281,-13.222142792586078,-19.697010927571476,-28.784937991351793,31.175629741216795,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-26,0.3840000033378601,0.3840000033378601,0.33799999952316284,0.3720000088214874,112929,0.0,0.0,0.4039000034332275,0.5026858277618885,0.7191398071746031,-7.897993151914834,-19.65160322272975,-30.09901235520964,34.07763189307359,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-29,0.37299999594688416,0.37299999594688416,0.31200000643730164,0.3449999988079071,243983,0.0,0.0,0.3915000021457672,0.4947478026151657,0.7142702490091324,-11.877395423499063,-20.868773933637602,-30.733807924731295,31.14073180643932,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-30,0.35499998927116394,0.35499998927116394,0.32899999618530273,0.33399999141693115,37449,0.0,0.0,0.38160000145435335,0.48764997720718384,0.7090680822730064,-12.473797132077861,-21.74715076583996,-31.226635439017247,30.00612996064004,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-31,0.33399999141693115,0.3540000021457672,0.3240000009536743,0.3540000021457672,158384,0.0,0.0,0.3703000009059906,0.48320000246167183,0.7044111989438534,-4.401836003333283,-23.365066428085676,-31.40370238489262,34.66702217716407,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-01,0.3310000002384186,0.3310000002384186,0.3240000009536743,0.32499998807907104,95612,0.0,0.0,0.35909999907016754,0.4749250017106533,0.6998224320511023,-9.495965212863565,-24.388061740967647,-32.13635631560129,31.401776013156464,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-02,0.3529999852180481,0.3529999852180481,0.3400000035762787,0.3490000069141388,35182,0.0,0.0,0.3555999994277954,0.4674500018358231,0.6955025071899096,-1.8560158954659238,-23.92769322253879,-32.78960219360013,36.714324050961444,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-05,0.3499999940395355,0.3499999940395355,0.3190000057220459,0.33399999141693115,189571,0.0,0.0,0.35,0.4608000010251999,0.6907133822639783,-4.57143102373395,-24.045139057875257,-33.286365537783894,34.89536647329666,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-07,0.36800000071525574,0.36800000071525574,0.31200000643730164,0.3269999921321869,112297,0.0,0.0,0.3458999991416931,0.45412500128149985,0.6862445491055648,-5.464008978434285,-23.83154458230785,-33.8246107931355,34.04762233816463,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-08,0.3269999921321869,0.36399999260902405,0.32600000500679016,0.36399999260902405,171762,0.0,0.0,0.346299996972084,0.44957500100135805,0.6823938325047493,5.111174066330372,-22.97169633525999,-34.11795658363763,42.0600409577081,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-09,0.35600000619888306,0.36800000071525574,0.3449999988079071,0.36800000071525574,58859,0.0,0.0,0.34719999730587003,0.4447750009596348,0.6777503577371439,5.990784438590214,-21.938059343092466,-34.37480395515562,42.86812306694424,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-12,0.36800000071525574,0.36800000071525574,0.3310000002384186,0.3619999885559082,160318,0.0,0.0,0.3461999952793121,0.44022499993443487,0.6742822490632534,4.563834053160154,-21.358397335255024,-34.71205855618809,41.9236015946238,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-13,0.3610000014305115,0.3619999885559082,0.3330000042915344,0.3619999885559082,49634,0.0,0.0,0.3478999942541122,0.4358249999582767,0.6705112405121326,4.052887190189805,-20.174383230099675,-35.00108967220354,41.923601594623804,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-14,0.38999998569488525,0.38999998569488525,0.335999995470047,0.3400000035762787,313039,0.0,0.0,0.348499995470047,0.4304749995470047,0.6668047239383061,-2.4390220959124465,-19.04291867430657,-35.44211909530009,38.33207326316413,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-15,0.3840000033378601,0.3840000033378601,0.3400000035762787,0.3499999940395355,266990,0.0,0.0,0.3480999946594238,0.4264249987900257,0.6632641486823558,0.5458199969151504,-18.36782654695383,-35.70811875824075,40.814069266991794,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-16,0.3790000081062317,0.3790000081062317,0.335999995470047,0.3490000069141388,146598,0.0,0.0,0.3504999965429306,0.4221499994397163,0.6596326321363449,-0.42795710230716266,-16.972640765576365,-36.00225657840732,40.63793136108532,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-19,0.33500000834465027,0.33500000834465027,0.30000001192092896,0.31700000166893005,360490,0.0,0.0,0.3472999960184097,0.4172749988734722,0.656216332068046,-8.724444197192998,-16.76951723539051,-36.41197597773243,35.376561061420304,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-20,0.3199999928474426,0.3499999940395355,0.3199999928474426,0.3370000123977661,396548,0.0,0.0,0.3475999981164932,0.41294999942183497,0.6534348152577877,-3.049478071393624,-15.825160769303134,-36.80318376379726,40.55663024261477,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-21,0.34700000286102295,0.34700000286102295,0.32899999618530273,0.33799999952316284,190133,0.0,0.0,0.34869999885559083,0.40829999968409536,0.6504964150488377,-3.0685401111398463,-14.597110182370187,-37.23255190369632,40.812092850750346,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-22,0.34200000762939453,0.3720000088214874,0.3109999895095825,0.3700000047683716,38817,0.0,0.0,0.34930000007152556,0.4039499990642071,0.6473703317344188,5.926139333698058,-13.528901873817064,-37.60140382368866,48.447220933560956,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-26,0.3889999985694885,0.3889999985694885,0.32499998807907104,0.34700000286102295,486444,0.0,0.0,0.3472000002861023,0.39912499859929085,0.6443279482424259,-0.05760294496387228,-13.009708360893631,-38.05561287726082,44.04895523793656,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-27,0.5,0.593999981880188,0.38199999928474426,0.41499999165534973,11937964,0.0,0.0,0.35250000059604647,0.3971499986946583,0.6423478816946347,17.730493887552136,-11.242603108489538,-38.17213226470028,56.595250368095314,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-28,0.41999998688697815,0.41999998688697815,0.38999998569488525,0.41600000858306885,1094153,0.0,0.0,0.35790000259876253,0.39464999958872793,0.6403073067466418,16.233586354410157,-9.312047897697516,-38.36553238882781,56.74884928709846,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-29,0.38999998569488525,0.4399999976158142,0.36500000953674316,0.3799999952316284,1247198,0.0,0.0,0.3619000017642975,0.3912500001490116,0.6374986151854197,5.001379767640706,-7.501597028379779,-38.62731763970741,49.902581115136904,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-30,0.3709999918937683,0.4350000023841858,0.3700000047683716,0.4269999861717224,1128656,0.0,0.0,0.36960000097751616,0.38917500004172323,0.6345583985249201,15.530298983331997,-5.029870639714381,-38.669947329293805,57.16777599109558,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-03,0.42500001192092896,0.5400000214576721,0.42500001192092896,0.4950000047683716,2736497,0.0,0.0,0.3842000007629395,0.38997500017285347,0.6317649235328039,28.839147263250098,-1.4808640059886582,-38.27213483266386,65.06224394259792,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-04,0.49900001287460327,0.5680000185966492,0.47999998927116394,0.5199999809265137,3502608,0.0,0.0,0.4044999986886978,0.39084999933838843,0.6285257985194524,28.553765787946116,3.4923882239773327,-37.8148040606973,67.43839114793494,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-05,0.5299999713897705,0.5299999713897705,0.47200000286102295,0.4790000021457672,2032752,0.0,0.0,0.4186999976634979,0.3900749996304512,0.625082690268755,14.401720759198902,7.338331874681896,-37.596256350861665,60.206521478439385,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-06,0.4819999933242798,0.48899999260902405,0.4099999964237213,0.4230000078678131,3232364,0.0,0.0,0.427199998497963,0.38932499960064887,0.6212761734922727,-0.9831438775554889,9.728375762194693,-37.33463213111758,52.00364439618889,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-07,0.4189999997615814,0.46000000834465027,0.41100001335144043,0.4300000071525574,713892,0.0,0.0,0.43319999873638154,0.38839999958872795,0.6174591486652692,-0.7386868866939872,11.53450030769613,-37.097053233673364,52.86807970704068,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-10,0.4300000071525574,0.47699999809265137,0.4000000059604645,0.42500001192092896,571532,0.0,0.0,0.44099999964237213,0.3872749999165535,0.613428357243538,-3.6281151325211627,13.872571102548525,-36.86711816571581,52.14564507219229,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-11,0.4399999976158142,0.4399999976158142,0.3869999945163727,0.3930000066757202,535345,0.0,0.0,0.4388000011444092,0.3853500001132488,0.6098468407988549,-10.437555685788661,13.870507594512052,-36.81200355019165,47.65717380617822,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-12,0.4099999964237213,0.41100001335144043,0.37400001287460327,0.40799999237060547,539805,0.0,0.0,0.4379999995231628,0.3838249996304512,0.6063283657034239,-6.849316708953753,14.114505294045884,-36.69684261181453,49.83684376191584,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-13,0.4399999976158142,0.44999998807907104,0.39100000262260437,0.42500001192092896,2569378,0.0,0.0,0.4425000011920929,0.38362499997019767,0.6027106155951818,-3.9547998246370697,15.347018892530198,-36.35005091268141,52.263070105351765,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-14,0.4180000126361847,0.4180000126361847,0.35600000619888306,0.3720000088214874,813726,0.0,0.0,0.4370000034570694,0.38125,0.5989403324822585,-14.874140531206548,14.622951726444441,-36.345913052817636,44.96175818004012,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-17,0.38999998569488525,0.38999998569488525,0.3580000102519989,0.3700000047683716,332258,0.0,0.0,0.4245000034570694,0.37957499995827676,0.5949330908556779,-12.838633273229059,11.835606534606029,-36.1987077551287,44.70793559348974,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-18,0.3779999911785126,0.38999998569488525,0.34599998593330383,0.3779999911785126,1093644,0.0,0.0,0.4103000044822693,0.37942499965429305,0.5898910656571388,-7.872291725785861,8.137314319327269,-35.67880211380833,46.02061292545072,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-19,0.36800000071525574,0.382999986410141,0.35199999809265137,0.36000001430511475,476440,0.0,0.0,0.39840000569820405,0.3786750003695488,0.5844236825903256,-9.6385519186408,5.208953669876703,-35.20539778758492,43.51724897178979,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-20,0.35499998927116394,0.4390000104904175,0.3160000145435333,0.38600000739097595,1986460,0.0,0.0,0.3947000056505203,0.3791250005364418,0.5797236911952496,-2.204205253355791,4.108145095164047,-34.60246557204207,47.92378173255356,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-21,0.3619999885559082,0.40700000524520874,0.3479999899864197,0.38100001215934753,1083955,0.0,0.0,0.38980000615119936,0.3796500004827976,0.5751541331410408,-2.2575664066147816,2.6735165693386187,-33.99160701333275,47.16178615998416,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-24,0.38100001215934753,0.38499999046325684,0.3499999940395355,0.367000013589859,339989,0.0,0.0,0.38400000631809234,0.3798500008881092,0.5700892833371957,-4.427081366803708,1.0925379545294687,-33.37008570577952,45.0040608578987,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-25,0.36800000071525574,0.3919999897480011,0.3409999907016754,0.3779999911785126,778769,0.0,0.0,0.3825000047683716,0.38000000044703486,0.5649784167607625,-1.1764741264732972,0.6578958732620293,-32.740793422566426,47.0537573031155,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-26,0.3799999952316284,0.3799999952316284,0.3499999940395355,0.3700000047683716,586064,0.0,0.0,0.3787000060081482,0.3806250005960464,0.559456683198611,-2.297333272180991,-0.5057457037461449,-31.96524198801609,45.71919267370815,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-27,0.3499999940395355,0.367000013589859,0.3409999907016754,0.367000013589859,342045,0.0,0.0,0.3729000061750412,0.38145000115036964,0.5534969083964825,-1.5821916029716325,-2.241445785697607,-31.083625696220096,45.20145103897951,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-28,0.367000013589859,0.4480000138282776,0.3529999852180481,0.41200000047683716,1937569,0.0,0.0,0.37690000534057616,0.3829000011086464,0.5472925670444966,9.312813647891508,-1.5669876601457042,-30.037419807034315,53.675688080139125,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-31,0.42800000309944153,0.44999998807907104,0.3799999952316284,0.4090000092983246,858754,0.0,0.0,0.3808000057935715,0.38500000163912773,0.5412353252371153,7.405462992571509,-1.0909080071882786,-28.866431349347128,53.08629338063969,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-01,0.41100001335144043,0.41999998688697815,0.3880000114440918,0.39899998903274536,863854,0.0,0.0,0.38290000557899473,0.3862500011920929,0.5355766336123149,4.204748816706168,-0.8673127774133343,-27.881468878329425,51.073095912103106,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-02,0.40400001406669617,0.4189999997615814,0.3880000114440918,0.3889999985694885,1017202,0.0,0.0,0.38580000400543213,0.38762500137090683,0.5295248255133629,0.8294438908329664,-0.4708151845263498,-26.79757724387846,49.06910610465642,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-03,0.421999990940094,0.421999990940094,0.3720000088214874,0.3930000066757202,1022344,0.0,0.0,0.38650000393390654,0.38927500173449514,0.5239538167913754,1.6817600713207765,-0.7128630886196188,-25.70432941621376,49.91565355094919,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-04,0.4000000059604645,0.42100000381469727,0.3779999911785126,0.414000004529953,728705,0.0,0.0,0.3898000031709671,0.3905250020325184,0.5187299085160096,6.208312252981628,-0.1856472332828866,-24.715156072311657,54.218022180415595,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-07,0.414000004529953,0.42899999022483826,0.4020000100135803,0.4169999957084656,473086,0.0,0.0,0.3948000013828278,0.39175000190734866,0.5134277420739333,5.6230988469807555,0.7785576159870626,-23.699097301419894,54.81517246943024,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-08,0.42800000309944153,0.42800000309944153,0.40299999713897705,0.4259999990463257,140475,0.0,0.0,0.39960000216960906,0.3933500021696091,0.5083382504681746,6.606605789133911,1.5889157151459814,-22.620420201049686,56.642275160621516,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-09,0.40299999713897705,0.49000000953674316,0.40299999713897705,0.48899999260902405,1520939,0.0,0.0,0.41150000095367434,0.39652500227093695,0.504496592283249,18.83353377296212,3.776558501222904,-21.401847240167577,66.77127427788298,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-10,0.48899999260902405,0.5400000214576721,0.45100000500679016,0.5080000162124634,4797992,0.0,0.0,0.4256000012159348,0.40072500258684157,0.5011918842792511,19.360905723945635,6.207498526050297,-20.045592285854333,69.11469497840051,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-11,0.5199999809265137,0.6100000143051147,0.5080000162124634,0.5839999914169312,5943132,0.0,0.0,0.44280000030994415,0.4065750025212765,0.49903681774934133,31.887983515842834,8.909794641585712,-18.528054832721185,76.31122538036522,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-14,0.593999981880188,0.6759999990463257,0.5239999890327454,0.5460000038146973,4409420,0.0,0.0,0.4564999997615814,0.4115000024437904,0.49670276790857315,19.605696407417195,10.93560074132389,-17.153672371011588,67.80411602132088,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-15,0.5440000295639038,0.6000000238418579,0.4860000014305115,0.4860000014305115,2822503,0.0,0.0,0.46520000100135805,0.41572500243782995,0.49389625142018,4.471195267493711,11.900895609694992,-15.827463512341222,56.99933701274292,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-16,0.49000000953674316,0.5239999890327454,0.4440000057220459,0.5220000147819519,3347825,0.0,0.0,0.4785000026226044,0.4203500024974346,0.49170640160640083,9.090911582221288,13.833709951155452,-14.511993107237462,61.01362699374663,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-17,0.5199999809265137,0.5360000133514404,0.4740000069141388,0.5,824534,0.0,0.0,0.4892000019550323,0.42440000250935556,0.48934698502222695,2.207685609527127,15.268614293716528,-13.272173835897119,57.4820335042124,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-18,0.4909999966621399,0.4909999966621399,0.44999998807907104,0.4819999933242798,985996,0.0,0.0,0.49600000083446505,0.4272000022232533,0.4868926430741946,-2.8225821545628635,16.104868504953128,-12.25991842350453,54.692656232770446,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-21,0.4830000102519989,0.49399998784065247,0.46299999952316284,0.47099998593330383,236714,0.0,0.0,0.5013999998569488,0.4303000018000603,0.48469083483020464,-6.063026312787839,16.52335527758731,-11.221758102605424,53.00004821713303,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-22,0.47200000286102295,0.4950000047683716,0.4300000071525574,0.4390000104904175,2693554,0.0,0.0,0.502700001001358,0.43090000227093694,0.4824288847545783,-12.671571590223344,16.662798410772673,-10.681135419545862,48.31562297766001,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-23,0.4390000104904175,0.4620000123977661,0.42800000309944153,0.4390000104904175,463615,0.0,0.0,0.4977000027894974,0.4314750023186207,0.4815437433620294,-11.79425195299971,15.348513845530537,-10.39754783103194,48.31562297766001,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-24,0.4620000123977661,0.4620000123977661,0.4259999990463257,0.4359999895095825,72448,0.0,0.0,0.4905000001192093,0.4328750021755695,0.4807024431725343,-11.111113271433497,13.31215654727683,-9.949489892606705,47.85572871143861,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-25,0.47099998593330383,0.47099998593330383,0.4169999957084656,0.4350000023841858,122103,0.0,0.0,0.47560000121593476,0.4330750025808811,0.4792057099441687,-8.536585098391436,9.81931498738759,-9.62649367610044,47.69276993403176,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-28,0.4359999895095825,0.46799999475479126,0.42100000381469727,0.44699999690055847,151662,0.0,0.0,0.4657000005245209,0.4318750023841858,0.4781394099195798,-4.015461370603494,7.83212687782405,-9.675924338296108,49.89759296725641,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-29,0.4959999918937683,0.5040000081062317,0.41600000858306885,0.4620000123977661,648449,0.0,0.0,0.46330000162124635,0.4304250031709671,0.47734955996274947,-0.2805933992944367,7.637799432674018,-9.830229401582393,52.58786894908411,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-30,0.4580000042915344,0.5139999985694885,0.4399999976158142,0.492000013589859,702083,0.0,0.0,0.46030000150203704,0.4307500034570694,0.4767133352657159,6.886815551679221,6.860127175347257,-9.641713039771998,57.50275311687276,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-31,0.5080000162124634,0.5080000162124634,0.45500001311302185,0.47699999809265137,152159,0.0,0.0,0.4580000013113022,0.4321000032126904,0.47600717668732007,4.148470901080826,5.99398238973472,-9.224057036323103,54.462720380682754,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-01,0.5120000243186951,0.5120000243186951,0.4300000071525574,0.44999998807907104,247621,0.0,0.0,0.4548000007867813,0.4326000027358532,0.474993409961462,-1.0554117632819837,5.13176095943843,-8.925051661042694,49.40011070349131,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-04,0.45500001311302185,0.48399999737739563,0.42100000381469727,0.4620000123977661,760226,0.0,0.0,0.45390000343322756,0.4335250027477741,0.4742999352514744,1.7845359998394736,4.699844427959712,-8.596866554932454,51.5554845811616,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-05,0.4740000069141388,0.4740000069141388,0.41999998688697815,0.46000000834465027,1163586,0.0,0.0,0.4560000032186508,0.4352000027894974,0.4732868934671084,0.8771941003872032,4.7794118326819515,-8.047315740903334,51.16430733912367,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-06,0.4690000116825104,0.4690000116825104,0.41999998688697815,0.46000000834465027,463175,0.0,0.0,0.4581000030040741,0.4365000031888485,0.4722463183104992,0.41475776645198215,4.948453529765613,-7.5694216631558096,51.16430733912367,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-07,0.45899999141693115,0.550000011920929,0.44999998807907104,0.5400000214576721,2895699,0.0,0.0,0.46850000619888305,0.4393750034272671,0.47188617661595345,15.261475840501182,6.628734576257527,-6.889621862169043,63.87859191933924,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-08,0.5180000066757202,0.656000018119812,0.5180000066757202,0.6259999871253967,3594202,0.0,0.0,0.48760000467300413,0.44572500288486483,0.47155429298679036,28.383917376130224,9.394806554963672,-5.477479578931345,72.24425497189429,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-11,0.6499999761581421,0.75,0.5820000171661377,0.6019999980926514,4050848,0.0,0.0,0.5031000047922134,0.4515250027179718,0.47052675957481066,19.658118139212682,11.422402250990293,-4.038400892227619,67.5430031759912,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-12,0.6019999980926514,0.6480000019073486,0.5299999713897705,0.550000011920929,2453700,0.0,0.0,0.5119000047445297,0.4558250032365322,0.46822604313492777,7.442861266511137,12.301870478767837,-2.648515621934767,58.639208018561476,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-13,0.550000011920929,0.6240000128746033,0.5260000228881836,0.593999981880188,1362836,0.0,0.0,0.5221000015735626,0.46167500242590903,0.46560358479619024,13.771304365049849,13.088211150732764,-0.8437611948372081,63.07479904191625,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-14,0.6000000238418579,0.6679999828338623,0.5720000267028809,0.656000018119812,1630712,0.0,0.0,0.5400000035762786,0.46842500269412995,0.4638764185210069,21.481484032462156,15.27992751678232,0.9805594747897393,68.24286667863853,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-15,0.6600000262260437,0.7979999780654907,0.6579999923706055,0.7580000162124634,3952308,0.0,0.0,0.5708000063896179,0.47785000279545786,0.46231084341804185,32.79607703701847,19.451711426262563,3.361192928664409,74.55295668465065,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-18,0.7860000133514404,0.7979999780654907,0.6919999718666077,0.7020000219345093,1525083,0.0,0.0,0.5948000073432922,0.4862250030040741,0.4604162854452928,18.022867059136736,22.330197679757806,5.605517957259129,66.71520356494784,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-19,0.7419999837875366,0.7900000214576721,0.6620000004768372,0.7879999876022339,2021878,0.0,0.0,0.6276000052690506,0.4964750029146671,0.45972027704119683,25.557677021436643,26.411199271783055,7.9950195170913885,71.64521614514888,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-20,0.8159999847412109,0.8199999928474426,0.7300000190734863,0.7680000066757202,1146545,0.0,0.0,0.6584000051021576,0.5064250029623508,0.460599268724521,16.646415662854842,30.00937972075305,9.9491547966911,69.08258164738184,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-21,0.7680000066757202,0.7799999713897705,0.6520000100135803,0.6880000233650208,2983840,0.0,0.0,0.6732000052928925,0.5144500032067298,0.46118332718809446,2.198457806857734,30.858198288779004,11.55000037477731,59.85947238003404,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-22,0.6880000233650208,0.7379999756813049,0.621999979019165,0.699999988079071,1061535,0.0,0.0,0.6806000053882599,0.5216500028967858,0.46258333548903463,2.8504235288308677,30.470622373009782,12.768870574489444,60.7068947083084,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-25,0.7379999756813049,0.7760000228881836,0.6000000238418579,0.6539999842643738,1603364,0.0,0.0,0.6858000040054322,0.527775002270937,0.4625666685402393,-4.6369232364143445,29.941736735263554,14.097067118234246,55.84027967912339,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-26,0.6320000290870667,0.6539999842643738,0.4869999885559082,0.6200000047683716,1137822,0.0,0.0,0.6928000032901764,0.5333000026643276,0.4623333352307479,-10.508082877608311,29.90811922538881,15.349675661643717,52.49079789790046,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-27,0.6460000276565552,0.6779999732971191,0.593999981880188,0.6520000100135803,209295,0.0,0.0,0.6986000061035156,0.5398750029504299,0.46276666844884556,-6.67048320681381,29.400324572475057,16.66246507339107,55.21369568833285,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-28,0.6700000166893005,0.6759999990463257,0.6200000047683716,0.6299999952316284,163502,0.0,0.0,0.6960000038146973,0.5458000026643276,0.46306666856010753,-9.482759801915272,27.519237892482053,17.86639802028442,52.96614460576155,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-29,0.6299999952316284,0.6480000019073486,0.5799999833106995,0.5899999737739563,365346,0.0,0.0,0.6791999995708465,0.5502000018954277,0.4634333349764347,-13.13310156849991,23.44601912595719,18.722577848959673,49.056133391040454,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-02,0.5899999737739563,0.6359999775886536,0.5559999942779541,0.6079999804496765,757647,0.0,0.0,0.6697999954223632,0.554975001513958,0.46383333479364713,-9.226637114817656,20.690120022553373,19.64965859145472,50.81569041411238,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-03,0.6079999804496765,0.6460000276565552,0.5799999833106995,0.6119999885559082,608262,0.0,0.0,0.6521999955177307,0.5596250012516976,0.4644000011185805,-6.163754559659391,16.542326389809823,20.504952606320558,51.218904669269115,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-04,0.6140000224113464,0.6460000276565552,0.5619999766349792,0.6340000033378601,245682,0.0,0.0,0.6387999951839447,0.5632500015199184,0.4652000012497107,-0.751407620894302,13.413225647608728,21.076956149356562,53.47790029762861,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-05,0.6600000262260437,0.6600000262260437,0.578000009059906,0.6119999885559082,486341,0.0,0.0,0.6311999917030334,0.5658500008285046,0.4656833343207836,-3.0418256336350566,11.54899545442165,21.5096094546346,50.93758915973619,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-06,0.6060000061988831,0.628000020980835,0.5799999833106995,0.6259999871253967,275182,0.0,0.0,0.623799991607666,0.5669000007212162,0.46663333401083945,0.35267642631108387,10.03704194991375,21.487249067390373,52.484404407753246,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-09,0.6299999952316284,0.6480000019073486,0.6119999885559082,0.6380000114440918,252735,0.0,0.0,0.6221999943256378,0.5692000009119511,0.46761666759848597,2.5393791807373187,9.31131295305201,21.72363398318568,53.82811572933454,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-10,0.6380000114440918,0.6940000057220459,0.5820000171661377,0.6779999732971191,1776290,0.0,0.0,0.6279999911785126,0.5740000002086163,0.4690000005066395,7.9617807039735755,9.407663928618529,22.388059613763343,58.08330574423587,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-11,0.6840000152587891,0.7459999918937683,0.6000000238418579,0.6399999856948853,1224814,0.0,0.0,0.6267999887466431,0.5769499994814395,0.47008333380023637,2.1059344583966917,8.640261601526742,22.733557647592875,53.07869654094303,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-12,0.6399999856948853,0.6520000100135803,0.5799999833106995,0.6039999723434448,570911,0.0,0.0,0.6241999864578247,0.5795499987900257,0.47075000032782555,-3.2361445934995605,7.704251188166422,23.112054888249155,48.789743695837934,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-13,0.6019999980926514,0.6439999938011169,0.5580000281333923,0.6019999980926514,426643,0.0,0.0,0.6253999888896942,0.582549998909235,0.47123333339889845,-3.741603967500231,7.355590088523114,23.622409031940684,48.55501211977849,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-16,0.6019999980926514,0.6019999980926514,0.5479999780654907,0.550000011920929,972294,0.0,0.0,0.6195999920368195,0.5845249995589257,0.4713166666527589,-11.233050518140512,6.0005974944375176,24.01959041893434,42.790601885148554,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-17,0.550000011920929,0.5680000185966492,0.5299999713897705,0.5400000214576721,210675,0.0,0.0,0.6123999953269958,0.587049999833107,0.4717000002662341,-11.822334164236104,4.318200409010409,24.454102077966454,41.763764913416914,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-18,0.6299999952316284,0.6299999952316284,0.5199999809265137,0.5460000038146973,302867,0.0,0.0,0.6035999953746796,0.589724999666214,0.47195000052452085,-9.542742213612442,2.3527908289997725,24.954973834261903,42.65296428461475,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-19,0.5460000038146973,0.6259999871253967,0.5199999809265137,0.6119999885559082,481787,0.0,0.0,0.6035999953746796,0.5941249996423721,0.4727500006556511,1.3916489803838406,1.5947815254383946,25.674246180515603,51.43692834153612,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-20,0.6200000047683716,0.6200000047683716,0.5640000104904175,0.6100000143051147,184245,0.0,0.0,0.6019999980926514,0.5984999999403954,0.47358333418766657,1.3289063517957236,0.5847950129665087,26.37691336140392,51.18109660699932,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-23,0.656000018119812,0.656000018119812,0.5580000281333923,0.5860000252723694,314595,0.0,0.0,0.5967999994754791,0.6019750006496907,0.4746083344022433,-1.809647153586079,-0.8596704462189207,26.83616300330299,48.09004741210092,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-24,0.5920000076293945,0.6299999952316284,0.5600000023841858,0.628000020980835,257181,0.0,0.0,0.5918000042438507,0.6061250008642673,0.47580000112454096,6.116934180025464,-2.363373330582104,27.390710263074112,53.39467343811395,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-25,0.6259999871253967,0.6460000276565552,0.5899999737739563,0.6159999966621399,628656,0.0,0.0,0.5894000053405761,0.6092250004410744,0.47668333450953165,4.513062619704822,-3.254133544445014,27.80497163130684,51.766973023144196,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-26,0.6460000276565552,0.6460000276565552,0.5120000243186951,0.5519999861717224,599658,0.0,0.0,0.5842000067234039,0.6111000001430511,0.4775083343187968,-5.511814478106801,-4.401897138496196,27.976823905038916,44.053657261727146,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-27,0.5540000200271606,0.6200000047683716,0.5339999794960022,0.5860000252723694,379727,0.0,0.0,0.5826000094413757,0.6145000010728836,0.47850000113248825,0.5835935077058773,-5.191210996877505,28.422152480359003,48.44822364029925,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-30,0.5860000252723694,0.5920000076293945,0.5619999766349792,0.5820000171661377,118446,0.0,0.0,0.5858000099658967,0.6175000011920929,0.47943333461880683,-0.6486843180457061,-5.133601808096998,28.797886296967995,47.97081795214783,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-31,0.5820000171661377,0.5960000157356262,0.550000011920929,0.5699999928474426,440978,0.0,0.0,0.5888000071048737,0.6202500008046627,0.48026666790246964,-3.1929371655191745,-5.070535051832062,29.147001500970347,46.49074812900345,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-01,0.5879999995231628,0.5879999995231628,0.5540000200271606,0.5659999847412109,96901,0.0,0.0,0.5908000051975251,0.6229000002145767,0.48107500101129214,-4.197701462108589,-5.153314337131774,29.480849951701305,45.98147425132442,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-02,0.5659999847412109,0.5920000076293945,0.5600000023841858,0.5759999752044678,68411,0.0,0.0,0.587200003862381,0.6237999990582466,0.4822666674852371,-1.9073618161177914,-5.867264387803896,29.34752515885664,47.528964420781996,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-03,0.5740000009536743,0.6000000238418579,0.550000011920929,0.5799999833106995,75142,0.0,0.0,0.5842000007629394,0.6226499989628792,0.483208333949248,-0.7189348590816382,-6.17521854396278,28.857462758139622,48.16858758568534,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-06,0.6100000143051147,0.6100000143051147,0.5600000023841858,0.5759999752044678,258634,0.0,0.0,0.5831999957561493,0.6219999983906745,0.48436666702230774,-1.2345714341692269,-6.237942561883281,28.41511209152385,47.54443762641665,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-07,0.5759999752044678,0.5979999899864197,0.5559999942779541,0.5580000281333923,147778,0.0,0.0,0.5761999964714051,0.6221999987959862,0.4858166672289371,-3.1586200016431176,-7.393121570812493,28.073003823637766,44.73531575220959,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-08,0.5519999861717224,0.5979999899864197,0.5519999861717224,0.5759999752044678,248192,0.0,0.0,0.5721999943256378,0.6217499986290932,0.487366667141517,0.6641001252207934,-7.969441803411175,27.573352990214907,48.041393376076115,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-09,0.5740000009536743,0.5740000009536743,0.5180000066757202,0.5659999847412109,294501,0.0,0.0,0.5735999941825867,0.6194999977946282,0.48901666700839996,-1.3249667919202452,-7.40920157795673,26.682798274437314,46.381341351664915,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-10,0.550000011920929,0.6859999895095825,0.5400000214576721,0.5960000157356262,523652,0.0,0.0,0.5745999932289123,0.6154499977827073,0.49098333368698754,3.7243339294973596,-6.637420537974814,25.350486575796864,51.7660893007658,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-13,0.6320000290870667,0.6320000290870667,0.47699999809265137,0.47699999809265137,1531297,0.0,0.0,0.5640999913215637,0.6098249971866607,0.49196666702628133,-15.440523766869063,-7.498053716401045,23.95656821076524,36.2253411079144,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-14,0.4620000123977661,0.4699999988079071,0.4300000071525574,0.4449999928474426,656847,0.0,0.0,0.5515999913215637,0.6012499973177909,0.49257500022649764,-19.325598287034225,-8.257797291928258,22.06262945568126,33.32785331673473,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-15,0.4449999928474426,0.46700000762939453,0.42100000381469727,0.4399999976158142,1040451,0.0,0.0,0.5389999926090241,0.5930499970912934,0.4933666668832302,-18.367346261732102,-9.113903506848661,20.204715255247706,32.88525016205183,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-16,0.4300000071525574,0.4699999988079071,0.42500001192092896,0.4359999895095825,1798775,0.0,0.0,0.5249999940395356,0.5867499962449074,0.4942166668673356,-16.952382007694048,-10.52407372825915,18.72323124270733,32.51324967574176,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-17,0.4690000116825104,0.4690000116825104,0.41100001335144043,0.414000004529953,596423,0.0,0.0,0.5083999961614609,0.5795999966561795,0.49471666688720384,-18.56805514245672,-12.284334179690239,17.157968479830725,30.47158859505511,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-20,0.414000004529953,0.41600000858306885,0.3919999897480011,0.40799999237060547,278607,0.0,0.0,0.4915999978780746,0.5734499968588352,0.4954083335896333,-17.005696881268786,-14.273258249037784,15.752997674408716,29.919770473945476,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-21,0.42100000381469727,0.4519999921321869,0.3930000066757202,0.41200000047683716,952156,0.0,0.0,0.47699999511241914,0.5682499967515469,0.4959333335359891,-13.626833396562784,-16.058073411485562,14.581932353677903,30.819226017516186,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-22,0.4099999964237213,0.4099999964237213,0.38100001215934753,0.3959999978542328,543825,0.0,0.0,0.4589999973773956,0.5618499964475632,0.4964500002563,-13.725490170616151,-18.30559752967204,13.173531303756558,29.204574038375256,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-23,0.4300000071525574,0.460999995470047,0.3700000047683716,0.4309999942779541,2549802,0.0,0.0,0.44549999833106996,0.5568749964237213,0.49731666694084803,-3.254770843419911,-19.999999785931685,11.97593675056888,36.982295888201264,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-24,0.4390000104904175,0.4390000104904175,0.35100001096725464,0.37599998712539673,1728230,0.0,0.0,0.423499995470047,0.5515249967575073,0.4974166668951511,-11.216058760975791,-23.212910029488636,10.877868286983137,31.184471845123582,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-27,0.3779999911785126,0.3930000066757202,0.3310000002384186,0.36399999260902405,781842,0.0,0.0,0.41219999492168424,0.5454249970614911,0.4973833334942659,-11.693353446503057,-24.425906927178673,9.658880853469332,30.07656712604735,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-28,0.3630000054836273,0.4129999876022339,0.3400000035762787,0.3880000114440918,1286143,0.0,0.0,0.4064999967813492,0.5398249976336956,0.4976000003516674,-4.55104193941932,-24.697819003708982,8.48573095904073,35.0468324455459,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-29,0.3889999985694885,0.43799999356269836,0.38100001215934753,0.41100001335144043,654787,0.0,0.0,0.4035999983549118,0.5342499978840352,0.4980083338916302,1.8335022365439486,-24.454843246902996,7.277320784814696,39.486115486925094,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-30,0.4189999997615814,0.4189999997615814,0.32100000977516174,0.35199999809265137,474260,0.0,0.0,0.3951999992132187,0.5277499981224537,0.4981083338459333,-10.931174394375445,-25.116058622605525,5.95084688659088,33.21486767330765,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-01,0.35199999809265137,0.3919999897480011,0.3199999928474426,0.3659999966621399,377533,0.0,0.0,0.39039999842643736,0.5212499983608723,0.4982416672011217,-6.25000047711197,-25.103117572356275,4.617905862630912,35.8196543028932,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-04,0.3659999966621399,0.3930000066757202,0.35100001096725464,0.3880000114440918,301352,0.0,0.0,0.388400000333786,0.5149999983608723,0.4985666672388713,-0.10298375112010288,-24.58252396699519,3.296115083868522,39.793537847128164,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-05,0.382999986410141,0.38499999046325684,0.3400000035762787,0.36000001430511475,515489,0.0,0.0,0.3832000017166138,0.5070499993860722,0.4989250006775061,-6.054276437257435,-24.42559862329434,1.6285010166924678,36.68060817382755,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-06,0.36000001430511475,0.3610000014305115,0.3400000035762787,0.35600000619888306,377748,0.0,0.0,0.3792000025510788,0.4999499998986721,0.4990833339591821,-6.118142456781932,-24.15241471588488,0.17365154885354497,36.244408494660995,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-07,0.36000001430511475,0.38999998569488525,0.3449999988079071,0.3569999933242798,605044,0.0,0.0,0.3718000024557114,0.493775000423193,0.49924166724085806,-3.9806371795800515,-24.70254627369595,-1.0949941033322594,36.44787695459222,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-08,0.3479999899864197,0.36000001430511475,0.32499998807907104,0.34700000286102295,491719,0.0,0.0,0.368900004029274,0.4874000005424023,0.49905000055829685,-5.9365684275007915,-24.312678781546122,-2.3344354278852775,35.23681779179225,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-11,0.34700000286102295,0.3720000088214874,0.3310000002384186,0.3400000035762787,1072836,0.0,0.0,0.36650000512599945,0.482150000333786,0.498991667230924,-7.230559666871026,-23.98631030337522,-3.375139907766024,34.37576730292716,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-12,0.33899998664855957,0.35899999737739563,0.32499998807907104,0.34700000286102295,939992,0.0,0.0,0.3624000042676926,0.4773249998688698,0.4984250006576379,-4.249448461731855,-24.076885902215317,-4.233335157933109,36.058440755031356,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-13,0.3400000035762787,0.3790000081062317,0.33000001311302185,0.3499999940395355,954720,0.0,0.0,0.35630000233650205,0.47242499962449075,0.4978750005364418,-1.7681752050668205,-24.580620708110537,-5.111725008190733,36.806293510976886,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-14,0.3580000102519989,0.4189999997615814,0.3440000116825104,0.4020000100135803,1799245,0.0,0.0,0.361300003528595,0.46717500016093255,0.49805833399295807,11.264878518542321,-22.66281299210483,-6.20074632311286,48.1306142978485,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-15,0.4050000011920929,0.4659999907016754,0.3700000047683716,0.37599998712539673,1823474,0.0,0.0,0.3623000025749207,0.46132499948143957,0.49763333400090537,3.781392341459619,-21.465343742010443,-7.296202251475329,43.89507187793295,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-18,0.37700000405311584,0.44999998807907104,0.37700000405311584,0.4000000059604645,2626695,0.0,0.0,0.3635000020265579,0.45667499899864195,0.4968416673441728,10.041266500801784,-20.402911737316522,-8.084400118902776,48.408325988822874,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-19,0.40799999237060547,0.44200000166893005,0.38199999928474426,0.42500001192092896,830866,0.0,0.0,0.37000000178813935,0.4515999987721443,0.49605000093579293,14.864867531617582,-18.069087069501162,-8.96079066219014,52.67863454669049,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-20,0.43299999833106995,0.46399998664855957,0.41600000858306885,0.46399998664855957,852625,0.0,0.0,0.380799999833107,0.4477999985218048,0.49592500080664953,21.84873604304533,-14.962036380050453,-9.704088764746029,58.45561464924863,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-21,0.46399998664855957,0.5979999899864197,0.4309999942779541,0.49000000953674316,1230383,0.0,0.0,0.3941000014543533,0.44624999910593033,0.4964833341538906,24.333927360692357,-11.686274006960325,-10.117829057357623,61.80343397832516,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-22,0.5479999780654907,0.5479999780654907,0.49300000071525574,0.5260000228881836,752020,0.0,0.0,0.4120000034570694,0.4447499990463257,0.4972833342850208,27.669907396734537,-7.363686488922287,-10.564065114755152,65.90082289205048,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-27,0.5260000228881836,0.5759999752044678,0.5099999904632568,0.5479999780654907,440467,0.0,0.0,0.4328000009059906,0.44389999806880953,0.49830833400289215,26.61736989795501,-2.500562561637661,-10.918608464165649,68.1493831617392,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-28,0.5519999861717224,0.5519999861717224,0.492000013589859,0.5,760407,0.0,0.0,0.4481000006198883,0.44214999824762347,0.49920000061392783,11.582235953652035,1.3456977034595796,-11.428285716374788,59.00684184845823,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-29,0.4950000047683716,0.5740000009536743,0.42899999022483826,0.4309999942779541,588928,0.0,0.0,0.4562000006437302,0.438774998486042,0.4993916672964891,-5.52389441696999,3.9712841929945273,-12.13810177062064,48.859606399822965,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-02,0.41999998688697815,0.41999998688697815,0.35100001096725464,0.38999998569488525,2013433,0.0,0.0,0.45499999821186066,0.43412499874830246,0.49910000041127206,-14.285717092840425,4.808522781168179,-13.018433502189625,44.01593369380122,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-03,0.4020000100135803,0.41999998688697815,0.36500000953674316,0.41499999165534973,1766799,0.0,0.0,0.458899998664856,0.4299999989569187,0.4994583336015542,-9.566355880852228,6.720930180940009,-13.906732548394379,47.43762372331059,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-04,0.41999998688697815,0.44999998807907104,0.4000000059604645,0.4099999964237213,1161991,0.0,0.0,0.4598999977111816,0.42584999948740004,0.4997916668653488,-10.850185156730015,7.99577275208827,-14.794497843812538,46.821265024765665,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-05,0.4020000100135803,0.40700000524520874,0.3919999897480011,0.40700000524520874,205278,0.0,0.0,0.4580999970436096,0.42207499891519545,0.500033333649238,-11.154767982575715,8.535212514601556,-15.590627561787413,46.43145058163769,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-08,0.4059999883174896,0.41600000858306885,0.39100000262260437,0.4009999930858612,915209,0.0,0.0,0.4517999976873398,0.4176999993622303,0.5003750001390775,-11.24391431197701,8.163753501837553,-16.522608194627633,45.61350379075404,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-09,0.4009999930858612,0.4320000112056732,0.4000000059604645,0.42100000381469727,1367528,0.0,0.0,0.44489999711513517,0.4140749998390675,0.5006666667759418,-5.371992235426528,7.4443029132519465,-17.295273019568892,48.84822104225588,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-10,0.421999990940094,0.4860000014305115,0.42100000381469727,0.4569999873638153,985966,0.0,0.0,0.43799999356269836,0.4105999991297722,0.5012999999026457,4.337898191863135,6.673159885776394,-18.09295846608574,54.13600695955988,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-11,0.4569999873638153,0.49900001287460327,0.4259999990463257,0.46299999952316284,1032247,0.0,0.0,0.4294999957084656,0.41024999916553495,0.5020999997854233,7.7997681372356205,4.692259983445681,-18.2931688227726,54.97148541235485,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-12,0.46399998664855957,0.5379999876022339,0.46000000834465027,0.5,1699808,0.0,0.0,0.4294999957084656,0.41162499934434893,0.5031166665256024,16.41443655319339,4.342543915600023,-18.18498039690714,59.83095811118137,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-15,0.5120000243186951,0.5440000295639038,0.4909999966621399,0.5400000214576721,392739,0.0,0.0,0.4403999984264374,0.41412499994039537,0.5045333333313465,22.6158091251382,6.344702321720199,-17.919199271532875,64.3146399442002,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-16,0.5440000295639038,0.5440000295639038,0.515999972820282,0.5299999713897705,867348,0.0,0.0,0.4543999969959259,0.4164749994874001,0.5058916663130124,16.63731841849515,9.10618825984853,-17.6750622277077,62.438260180592714,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-17,0.527999997138977,0.5299999713897705,0.48500001430511475,0.5099999904632568,1158364,0.0,0.0,0.4638999968767166,0.4188749991357327,0.5067083328962326,9.937485211665454,10.749029623129646,-17.334100913332936,58.74672790038332,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-18,0.5099999904632568,0.527999997138977,0.4399999976158142,0.4790000021457672,1268531,0.0,0.0,0.4707999974489212,0.4206499993801117,0.5072916661699612,1.7417172347660552,11.922024995296024,-17.079260821292774,53.469801010269904,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-19,0.4749999940395355,0.4749999940395355,0.4519999921321869,0.4699999988079071,312885,0.0,0.0,0.47709999680519105,0.42209999933838843,0.5078833329180876,-1.488157209144357,13.030087077235533,-16.89036202208559,52.009161412390974,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-22,0.4699999988079071,0.5360000133514404,0.4699999988079071,0.4880000054836273,759957,0.0,0.0,0.48579999804496765,0.42439999952912333,0.5087083329757055,0.4528627928187077,14.46748317247133,-16.57301993726305,54.675887968040904,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-23,0.5,0.5180000066757202,0.4620000123977661,0.5,333478,0.0,0.0,0.4936999976634979,0.42612499967217443,0.5095999995867412,1.2760790695397384,15.85802242142802,-16.38049450201346,56.41470236626399,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-24,0.5,0.5360000133514404,0.49000000953674316,0.5199999809265137,417211,0.0,0.0,0.4999999970197678,0.4297249995172024,0.5104833327233791,3.9999968051910186,16.353481315147967,-15.819974527931954,59.22257218183342,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-25,0.5199999809265137,0.527999997138977,0.5,0.5180000066757202,533063,0.0,0.0,0.5054999977350235,0.43357499986886977,0.5113249994814396,2.4728009884678643,16.58882497558824,-15.205593251145558,58.81453370609994,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-26,0.5180000066757202,0.5379999876022339,0.5099999904632568,0.5239999890327454,238460,0.0,0.0,0.507899996638298,0.43697499930858613,0.5121416660646597,3.169913861195202,16.230905072815283,-14.676928618923094,59.711356722859705,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-29,0.5299999713897705,0.5299999713897705,0.48500001430511475,0.4959999918937683,834904,0.0,0.0,0.5034999936819077,0.43909999877214434,0.5121999993920326,-1.489573362910027,14.666361897026894,-14.271768978261617,53.82142026665475,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-30,0.4950000047683716,0.5180000066757202,0.4650000035762787,0.49000000953674316,373362,0.0,0.0,0.4994999974966049,0.4425499990582466,0.5120499993364016,-1.9018995009957542,12.86860209231698,-13.572893344053218,52.623548119203186,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-31,0.47999998927116394,0.5360000133514404,0.47600001096725464,0.4880000054836273,240558,0.0,0.0,0.49729999899864197,0.4455999992787838,0.511249999453624,-1.8700972317999232,11.602333887687632,-12.841075842542942,52.206443492564254,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-01,0.47099998593330383,0.48899999260902405,0.367000013589859,0.4490000009536743,2740574,0.0,0.0,0.49429999887943266,0.44712499901652336,0.5104416660964489,-9.164474616316499,10.55074083682938,-12.404290496920712,44.75669877150658,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-02,0.4480000138282776,0.47699999809265137,0.4339999854564667,0.4749999940395355,810974,0.0,0.0,0.49479999840259553,0.44999999850988387,0.5103499993681908,-4.001617709575997,9.955555564680223,-11.825218170475116,49.89040951230917,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-05,0.4749999940395355,0.48100000619888306,0.4399999976158142,0.4749999940395355,482687,0.0,0.0,0.49349999725818633,0.4529749982059002,0.5099583325286706,-3.7487342090038736,8.946409672232164,-11.17411574396948,49.89040951230917,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-06,0.4749999940395355,0.4779999852180481,0.44999998807907104,0.47600001096725464,472143,0.0,0.0,0.4910999983549118,0.45594999864697455,0.5097583326200644,-3.074727639633302,7.709178596829565,-10.555655597923215,50.09727095722948,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-07,0.47600001096725464,0.5299999713897705,0.46000000834465027,0.4779999852180481,1610182,0.0,0.0,0.48689999878406526,0.4592249982059002,0.5097249992191791,-1.8278935280844435,6.026457768258641,-9.907303171442884,50.53705594311811,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-08,0.4779999852180481,0.4869999885559082,0.4009999930858612,0.44699999690055847,848030,0.0,0.0,0.4797999978065491,0.46189999803900716,0.5095249993105729,-6.836181962471636,3.875297649607324,-9.346941040381946,44.05603636744611,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-09,0.44600000977516174,0.492000013589859,0.41999998688697815,0.4390000104904175,443282,0.0,0.0,0.4712999999523163,0.46419999822974206,0.5095249993105729,-6.8533820210411145,1.5295135178049504,-8.895540187853223,42.539886527321876,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-12,0.4390000104904175,0.4729999899864197,0.42100000381469727,0.44200000166893005,492353,0.0,0.0,0.46590000092983247,0.4664999984204769,0.5095499992370606,-5.129856023439225,-0.1286168258683741,-8.448631318033874,43.32752030008143,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-13,0.4259999990463257,0.4480000138282776,0.4099999964237213,0.42100000381469727,468406,0.0,0.0,0.4590000003576279,0.4669749982655048,0.5094249993562698,-8.278866342771915,-1.7077997617642546,-8.332924600168145,39.269644280349866,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-14,0.4099999964237213,0.4449999928474426,0.4090000092983246,0.421999990940094,274551,0.0,0.0,0.45239999890327454,0.4681249983608723,0.5093166659275691,-6.719718841042751,-3.35914542326482,-8.08763394609882,39.55992605407249,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-15,0.43700000643730164,0.43700000643730164,0.38600000739097595,0.4169999957084656,978779,0.0,0.0,0.4491999983787537,0.4685499981045723,0.5090666659176349,-7.168299818901136,-4.129761989989389,-7.959010189761289,38.56728356881919,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-16,0.40299999713897705,0.4519999921321869,0.4009999930858612,0.43299999833106995,356316,0.0,0.0,0.4449999988079071,0.46874999776482584,0.5088249991337458,-2.6966293278614524,-5.066666468302417,-7.875989080164307,43.45666537697598,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-19,0.43299999833106995,0.45399999618530273,0.42800000309944153,0.4480000138282776,689119,0.0,0.0,0.44230000078678133,0.4683499984443188,0.508458332469066,1.2887210109330405,-5.562079159616885,-7.888224356552829,47.662243210292594,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-20,0.44999998807907104,0.44999998807907104,0.41999998688697815,0.4339999854564667,164125,0.0,0.0,0.4380999982357025,0.46694999784231184,0.5080999990304311,-0.9358623135693276,-6.178391635061518,-8.098799698217423,44.34689345368433,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-21,0.4339999854564667,0.4339999854564667,0.39899998903274536,0.41999998688697815,334035,0.0,0.0,0.43229999840259553,0.46429999694228175,0.507849999020497,-2.845249031012611,-6.892095358696333,-8.57536716790612,41.25638587849163,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-22,0.4189999997615814,0.4779999852180481,0.4009999930858612,0.42100000381469727,498300,0.0,0.0,0.4296999990940094,0.4611249975860119,0.5075083322823047,-2.0246672789516964,-6.814854682897751,-9.139423285466735,41.56962021480176,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-23,0.44600000977516174,0.45899999141693115,0.36000001430511475,0.4090000092983246,1532923,0.0,0.0,0.4266999989748001,0.45884999781847,0.507083332290252,-4.148111019217704,-7.006646833719523,-9.511914788035963,38.88981656404306,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-26,0.4090000092983246,0.4180000126361847,0.3799999952316284,0.4020000100135803,431290,0.0,0.0,0.42269999980926515,0.45812499821186065,0.5065999989708264,-4.897087722977355,-7.732605411375773,-9.56869341836641,37.37617379804128,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-27,0.4020000100135803,0.42800000309944153,0.38999998569488525,0.4180000126361847,1264955,0.0,0.0,0.42240000069141387,0.45882499888539313,0.5055833322306474,-1.0416638371275966,-7.9387562322160266,-9.248392967971327,42.851374298935745,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-28,0.4189999997615814,0.42500001192092896,0.39800000190734863,0.41200000047683716,259153,0.0,0.0,0.4214000016450882,0.45874999910593034,0.5037999990085761,-2.2306599742654707,-8.141688835669655,-8.942040490531813,41.38996375951823,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-29,0.38999998569488525,0.41200000047683716,0.382999986410141,0.4059999883174896,333222,0.0,0.0,0.4203000009059906,0.4586499989032745,0.5021666655937831,-3.402334655645055,-8.361495277223709,-8.665781636272616,39.9236646770231,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-01,0.4180000126361847,0.4180000126361847,0.3889999985694885,0.4020000100135803,588736,0.0,0.0,0.4172000020742416,0.45852499902248384,0.5009333322445552,-3.64333460812314,-9.012594086765557,-8.46586371724364,38.93342501750106,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-04,0.4020000100135803,0.4099999964237213,0.3799999952316284,0.4020000100135803,478859,0.0,0.0,0.4126000016927719,0.4585499994456768,0.4993333324790001,-2.569072136622161,-10.020717001079944,-8.167556696215238,38.93342501750106,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-05,0.41499999165534973,0.4300000071525574,0.4000000059604645,0.4189999997615814,358565,0.0,0.0,0.4111000031232834,0.45849999934434893,0.49735833232601484,1.9216727264117637,-10.338058078265462,-7.812945004849049,45.585879631322946,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-06,0.4189999997615814,0.4300000071525574,0.3799999952316284,0.40299999713897705,1058525,0.0,0.0,0.40940000414848327,0.45714999958872793,0.4943999988337358,-1.5632650084646866,-10.445148306508289,-7.534384978333073,41.05295161147841,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-07,0.4189999997615814,0.4189999997615814,0.3799999952316284,0.38999998569488525,496913,0.0,0.0,0.4063000023365021,0.455324999243021,0.4917999985317389,-4.01181800341635,-10.767033874270705,-7.416632655065763,37.76694311778662,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-08,0.38999998569488525,0.38999998569488525,0.36399999260902405,0.36500000953674316,478273,0.0,0.0,0.40190000236034396,0.4519499994814396,0.4882749987145265,-9.181386565535828,-11.074233251138894,-7.439455087546798,32.39657627049331,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-11,0.3630000054836273,0.4000000059604645,0.36000001430511475,0.38600000739097595,341332,0.0,0.0,0.4003000020980835,0.44809999912977216,0.48509166538715365,-3.572319418475463,-10.667261130220524,-7.625706417334192,40.10156383578665,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-12,0.3799999952316284,0.3889999985694885,0.3700000047683716,0.37700000405311584,356626,0.0,0.0,0.3962000012397766,0.44427499994635583,0.48249999855955444,-4.846036629626638,-10.821000216618998,-7.922279528977147,38.097516302425525,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-13,0.37599998712539673,0.3779999911785126,0.33399999141693115,0.3569999933242798,1452573,0.0,0.0,0.39070000052452086,0.44045000001788137,0.4796416652699312,-8.625545726899999,-11.295266089531333,-8.171030185626941,34.02789469267326,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-14,0.3580000102519989,0.36800000071525574,0.34599998593330383,0.35600000619888306,345867,0.0,0.0,0.3857000023126602,0.43737500011920927,0.4771583321193854,-7.700284142000455,-11.814803725056235,-8.337553663470834,33.83329126833016,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-15,0.35600000619888306,0.3709999918937683,0.3330000042915344,0.35899999737739563,471996,0.0,0.0,0.38140000104904176,0.4346000000834465,0.4749833320577939,-5.873100055069443,-12.241141054806707,-8.50205244032305,35.0336583095429,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-18,0.35899999737739563,0.3700000047683716,0.3490000069141388,0.36500000953674316,78736,0.0,0.0,0.37770000100135803,0.4315250001847744,0.47259166538715364,-3.3624547076898748,-12.473205297576985,-8.689671911318378,37.4767128847821,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-19,0.3540000021457672,0.3700000047683716,0.35199999809265137,0.367000013589859,27759,0.0,0.0,0.3725000023841858,0.4282000005245209,0.4703999988734722,-1.4765070494292916,-13.007939764620676,-8.971088105870137,38.30948576917657,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-20,0.37400001287460327,0.37400001287460327,0.35100001096725464,0.367000013589859,323797,0.0,0.0,0.368900004029274,0.4243750013411045,0.4685416658719381,-0.515042130296153,-13.072164273701127,-9.426411298692315,38.30948576917656,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-21,0.3779999911785126,0.4180000126361847,0.36800000071525574,0.3880000114440918,723792,0.0,0.0,0.36870000660419466,0.4211250014603138,0.46670833279689156,5.234609301381433,-12.44879659823749,-9.76698467400524,46.919050529013376,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-22,0.3880000114440918,0.3919999897480011,0.36899998784065247,0.38600000739097595,253538,0.0,0.0,0.3708000063896179,0.41767500191926954,0.4648249996205171,4.0992450753592085,-11.222839603580557,-10.143601944762178,46.25693170137675,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-25,0.38600000739097595,0.4180000126361847,0.36500000953674316,0.37400001287460327,417481,0.0,0.0,0.3696000069379807,0.4146250024437904,0.46265833303332327,1.1904777743580843,-10.859208981714424,-10.382030790326912,42.391480769554455,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-26,0.37299999594688416,0.38499999046325684,0.3659999966621399,0.3799999952316284,103933,0.0,0.0,0.3699000060558319,0.41187500208616257,0.460724999755621,2.730464723018158,-10.19119777061626,-10.602853696970984,44.87203602183335,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-27,0.3799999952316284,0.3799999952316284,0.367000013589859,0.37700000405311584,288255,0.0,0.0,0.3719000071287155,0.40910000205039976,0.45864999989668526,1.371335527464835,-9.093129976836648,-10.8034444254763,43.855229624934296,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-28,0.3700000047683716,0.3799999952316284,0.3610000014305115,0.3610000014305115,238548,0.0,0.0,0.37240000665187833,0.4069000020623207,0.45634166647990543,-3.061225837201354,-8.478740534672777,-10.83435242697959,38.80475493786329,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-02,0.36000001430511475,0.36000001430511475,0.32199999690055847,0.34200000762939453,845306,0.0,0.0,0.3707000076770782,0.4035750024020672,0.45354166676600777,-7.742109375051498,-8.145944255545535,-11.016995355736412,33.8234132750526,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-03,0.34200000762939453,0.34200000762939453,0.328000009059906,0.3384999930858612,251237,0.0,0.0,0.36805000603199006,0.4001625023782253,0.4510291668275992,-8.02880382063095,-8.024863937871716,-11.277910208591251,32.98345331924301,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-04,0.3384999930858612,0.3384999930858612,0.30550000071525574,0.3269999921321869,373511,0.0,0.0,0.36405000388622283,0.3964375019073486,0.44872083365917204,-10.177176585229551,-8.169635280542925,-11.651639021408904,30.319222088255955,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-05,0.3269999921321869,0.32899999618530273,0.3149999976158142,0.3165000081062317,102668,0.0,0.0,0.3590000033378601,0.3924000024795532,0.4463416670759519,-11.838438673113615,-8.511722459388489,-12.085285460749894,28.088336699553082,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-08,0.3165000081062317,0.3165000081062317,0.3005000054836273,0.3009999990463257,783475,0.0,0.0,0.3503000020980835,0.3887500025331974,0.4442666669686635,-14.073651943043345,-9.890675288633723,-12.496247988684235,25.14682632644299,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-09,0.3009999990463257,0.3294999897480011,0.30000001192092896,0.31200000643730164,465300,0.0,0.0,0.3429000020027161,0.3855750024318695,0.4423666668434938,-9.011372232412437,-11.067885666860368,-12.838142805121617,30.6938715817289,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-10,0.31200000643730164,0.32850000262260437,0.30399999022483826,0.30399999022483826,197751,0.0,0.0,0.33589999973773954,0.3821250021457672,0.4403500000635783,-9.496876909141957,-12.096827516770146,-13.222436223323369,29.010099580310452,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-11,0.3034999966621399,0.3199999928474426,0.28999999165534973,0.3009999990463257,205505,0.0,0.0,0.32800000011920927,0.3791250020265579,0.43775833348433174,-8.23170764118007,-13.484998782477373,-13.393995493148603,28.381348941917906,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-12,0.3009999990463257,0.3095000088214874,0.2849999964237213,0.3050000071525574,159929,0.0,0.0,0.32080000042915346,0.3762000024318695,0.4352166667580605,-4.9251849300060755,-14.726209900211016,-13.560295097567728,30.542928694580553,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-15,0.304500013589859,0.304500013589859,0.28999999165534973,0.2955000102519989,152139,0.0,0.0,0.3142500013113022,0.3731625027954578,0.43279583329955734,-5.966584242184043,-15.787358333923335,-13.778628608659602,28.35411639603491,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-16,0.2955000102519989,0.30000001192092896,0.2815000116825104,0.29649999737739563,131894,0.0,0.0,0.3097000002861023,0.36975000277161596,0.430033333102862,-4.262190150633655,-16.24070372829851,-14.01829246497656,28.931455391349857,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-17,0.2980000078678131,0.2980000078678131,0.2879999876022339,0.296999990940094,304200,0.0,0.0,0.30555000007152555,0.36597500219941137,0.427374999721845,-2.798235683007725,-16.510691103148524,-14.366773340133498,29.238492883990602,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-18,0.296999990940094,0.30799999833106995,0.28999999165534973,0.28999999165534973,222854,0.0,0.0,0.3018500000238419,0.36237500235438347,0.4251916664342085,-3.9257937278635637,-16.702311676386376,-14.773728894224439,27.450435339198407,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-19,0.29249998927116394,0.36000001430511475,0.25999999046325684,0.33899998664855957,969490,0.0,0.0,0.3040999978780746,0.360350002348423,0.42313333277901016,11.476484384744289,-15.609824921260904,-14.837717940641893,50.34282901531396,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-22,0.33899998664855957,0.37400001287460327,0.3199999928474426,0.33000001311302185,724176,0.0,0.0,0.30699999928474425,0.3580750025808811,0.4210333327452342,7.491861199304093,-14.263772373945638,-14.953288793989373,47.385294259197515,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-23,0.33000001311302185,0.4000000059604645,0.3294999897480011,0.3700000047683716,830885,0.0,0.0,0.3127999991178513,0.3571000024676323,0.4193666661779086,18.286446870790908,-12.405489510965879,-14.847785656826812,58.93285184436286,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-24,0.3700000047683716,0.3799999952316284,0.35350000858306885,0.35499998927116394,333261,0.0,0.0,0.31789999902248384,0.3559250019490719,0.41760833288232485,11.670333552299308,-10.68343126174343,-14.770617843642095,54.13468753895657,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-25,0.3544999957084656,0.35499998927116394,0.3154999911785126,0.3269999921321869,409528,0.0,0.0,0.32049999833106996,0.35365000143647196,0.4155333330233892,2.0280791996768035,-9.373675376997536,-14.892507211553587,46.520659325986095,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-26,0.33000001311302185,0.3855000138282776,0.30000001192092896,0.359499990940094,614831,0.0,0.0,0.3259499967098236,0.35233750119805335,0.41369583308696745,10.292988056121445,-7.489269350694802,-14.831750039893512,54.51710496136488,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-29,0.359499990940094,0.359499990940094,0.3154999911785126,0.3310000002384186,476041,0.0,0.0,0.32949999570846555,0.3504625014960766,0.4116541666289171,0.45523658558108043,-5.981383371437736,-14.864823459445581,47.771432286400234,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-30,0.3310000002384186,0.3400000035762787,0.3059999942779541,0.3400000035762787,134408,0.0,0.0,0.3338499963283539,0.34891250133514407,0.4098374997576078,1.8421468670246872,-4.316986335872803,-14.865647594106665,49.88045955170234,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-02,0.3395000100135803,0.3395000100135803,0.28999999165534973,0.3154999911785126,429165,0.0,0.0,0.3356999963521957,0.3467500008642673,0.4076666665573915,-6.017278937498273,-3.1867352514865748,-14.942763461026873,44.600592105766395,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-03,0.3070000112056732,0.32249999046325684,0.2800000011920929,0.31150001287460327,642485,0.0,0.0,0.3378499984741211,0.3440625011920929,0.4055458334585031,-7.799314997343776,-1.8056320280318228,-15.160637144778205,43.78569857252853,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-06,0.2994999885559082,0.30300000309944153,0.28999999165534973,0.30000001192092896,584077,0.0,0.0,0.333950001001358,0.3414875015616417,0.4030791667600473,-10.166189243488281,-2.20725517795359,-15.280289897758733,41.441365940584504,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-07,0.30649998784065247,0.30649998784065247,0.25099998712539673,0.27900001406669617,687618,0.0,0.0,0.32885000109672546,0.33871250227093697,0.4014291668931643,-15.158883035967149,-2.9117617767538038,-15.623345236126967,37.49361025463158,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-08,0.27300000190734863,0.29899999499320984,0.27000001072883606,0.27649998664855957,119978,0.0,0.0,0.31949999928474426,0.3365000016987324,0.4000250001748403,-13.458532936603323,-5.052006635413986,-15.880257096017198,37.041221592813685,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-10,0.2759999930858612,0.2994999885559082,0.26899999380111694,0.27950000762939453,288830,0.0,0.0,0.3119500011205673,0.33383750170469284,0.3986875002582868,-10.402305938325993,-6.556333687006457,-16.265872020462485,38.00784079445137,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-13,0.27250000834465027,0.2800000011920929,0.257999986410141,0.2784999907016754,384601,0.0,0.0,0.30710000097751616,0.3313750013709068,0.3973750002682209,-9.312930701662438,-7.325537621415119,-16.6089962510891,37.7995102059872,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-14,0.27799999713897705,0.2980000078678131,0.25049999356269836,0.28700000047683716,725499,0.0,0.0,0.2998500019311905,0.32962500154972074,0.3963166669011116,-4.28547652879527,-9.032991878208298,-16.827872991784037,40.771239487293414,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-15,0.289000004529953,0.28999999165534973,0.2800000011920929,0.28700000047683716,685622,0.0,0.0,0.29545000195503235,0.32790000140666964,0.3953083336353302,-2.8600444820715505,-9.896309640874934,-17.052089848134692,40.771239487293414,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-16,0.2750000059604645,0.3100000023841858,0.2750000059604645,0.2939999997615814,740497,0.0,0.0,0.2908500015735626,0.32627500146627425,0.3943250002960364,1.0830318621202082,-10.857405481116327,-17.257338180098685,43.35598281029602,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-17,0.3034999966621399,0.359499990940094,0.29600000381469727,0.3540000021457672,1408267,0.0,0.0,0.29470000267028806,0.32600000128149986,0.39397500033179916,20.122157766596395,-9.60122653011414,-17.253632589136846,59.62163450101299,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-20,0.3799999952316284,0.3799999952316284,0.28999999165534973,0.32100000977516174,2093654,0.0,0.0,0.29565000236034394,0.32485000118613244,0.3930583337942759,8.574330191927656,-8.98876365066026,-17.35323404791189,50.954982911088344,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-21,0.32100000977516174,0.3400000035762787,0.27250000834465027,0.28299999237060547,1195118,0.0,0.0,0.2939500004053116,0.32275000065565107,0.39228333383798597,-3.7251260485142947,-8.923315318925995,-17.72528353474541,43.172634796219945,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-22,0.28299999237060547,0.3059999942779541,0.2605000138282776,0.3059999942779541,712750,0.0,0.0,0.29664999842643736,0.32070000022649764,0.3918000005185604,3.151861082458538,-7.499221011248745,-18.14701383306777,48.31773989512287,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-23,0.3050000071525574,0.3050000071525574,0.25999999046325684,0.2750000059604645,813649,0.0,0.0,0.29650000035762786,0.3179250001907349,0.39085833380619683,-7.25126285707617,-6.739010716443622,-18.659787270040713,42.70546966559914,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-24,0.2750000059604645,0.3190000057220459,0.2750000059604645,0.28600001335144043,460095,0.0,0.0,0.29715000092983246,0.3157250002026558,0.38981666713953017,-3.7523094543166207,-5.883284269823593,-19.0067981137282,45.14047617363389,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-27,0.28600001335144043,0.3009999990463257,0.23999999463558197,0.29350000619888306,560562,0.0,0.0,0.2986500024795532,0.31356250047683715,0.3893291672070821,-1.724425326607099,-4.755829531467056,-19.460824698485812,46.800621388010875,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-28,0.2930000126361847,0.2930000126361847,0.25049999356269836,0.2865000069141388,1078907,0.0,0.0,0.2986000031232834,0.3113000005483627,0.3886666672925154,-4.052242492492155,-4.07966508278444,-19.905660365241864,45.41910992412299,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-29,0.2865000069141388,0.3009999990463257,0.25999999046325684,0.2994999885559082,928159,0.0,0.0,0.2998500019311905,0.30976250022649765,0.38792916710178055,-0.11672948908721655,-3.200031730134914,-20.149726678008307,48.461825330455575,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-30,0.30000001192092896,0.31949999928474426,0.28999999165534973,0.30000001192092896,614237,0.0,0.0,0.3004500031471252,0.308712500333786,0.3874291670819124,-0.1497724152047733,-2.676437519610383,-20.317692480670583,48.580560752103004,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-31,0.30799999833106995,0.30799999833106995,0.2800000011920929,0.2915000021457672,131499,0.0,0.0,0.29420000314712524,0.30753750056028367,0.3868916670481364,-0.9177433625001696,-4.336868638413091,-20.51069414167031,46.614547032184625,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-03,0.2800000011920929,0.2879999876022339,0.25049999356269836,0.27900001406669617,415049,0.0,0.0,0.2900000035762787,0.3063375011086464,0.38624166722098985,-3.793099784114038,-5.333169289832846,-20.687609052450043,43.80690674159223,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-04,0.2605000138282776,0.27900001406669617,0.2554999887943268,0.2694999873638153,752469,0.0,0.0,0.2886500030755997,0.305162500590086,0.38559583375851314,-6.63433760877835,-5.411050664008996,-20.859492278332056,41.74881802057736,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-05,0.2694999873638153,0.2800000011920929,0.2630000114440918,0.2800000011920929,140780,0.0,0.0,0.28605000376701356,0.3046375006437302,0.3850958337386449,-2.1150157298541292,-6.101513056481669,-20.8930676589765,44.83374396840704,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-07,0.2800000011920929,0.2800000011920929,0.25049999356269836,0.27900001406669617,235618,0.0,0.0,0.2864500045776367,0.30381250083446504,0.38452916716535884,-2.6007995782458977,-5.714872235059365,-20.991038709992907,44.59153975649902,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-10,0.27900001406669617,0.27950000762939453,0.25850000977516174,0.26649999618530273,318371,0.0,0.0,0.28450000286102295,0.30287500098347664,0.3838333338499069,-6.326891562286958,-6.0668586257655965,-21.092053692785314,41.56851241024618,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-11,0.2554999887943268,0.2784999907016754,0.25049999356269836,0.2759999930858612,278146,0.0,0.0,0.28275000154972074,0.302250000834465,0.3827833337088426,-2.387270884832362,-6.451612648770165,-21.038881733454424,44.640230751036526,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-12,0.2615000009536743,0.2879999876022339,0.25999999046325684,0.2879999876022339,497647,0.0,0.0,0.2828999996185303,0.3018250003457069,0.3820500003794829,1.8027529128952093,-6.270189913194779,-20.99856038583694,48.334887483889325,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-13,0.2874999940395355,0.2874999940395355,0.25,0.2669999897480011,488935,0.0,0.0,0.2796499997377396,0.301112499833107,0.3809416669110457,-4.523515108743738,-7.127734686292706,-20.955745724864414,42.93467454786096,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-14,0.26899999380111694,0.2770000100135803,0.2615000009536743,0.2750000059604645,218671,0.0,0.0,0.27714999914169314,0.3005750000476837,0.3796916668613752,-0.7757507443214801,-7.793396291200002,-20.83708274866533,45.43568320344379,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-17,0.27399998903274536,0.3269999921321869,0.26249998807907104,0.28450000286102295,334850,0.0,0.0,0.27644999921321867,0.30026250034570695,0.3781958336631457,2.911920300493662,-7.930561127370811,-20.606608106331752,48.33159437644886,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-18,0.28349998593330383,0.29899999499320984,0.27549999952316284,0.296999990940094,75254,0.0,0.0,0.27824999690055846,0.30043750032782557,0.3765875001748403,6.738542407328918,-7.385064581837147,-20.22106411170316,51.945535518546585,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-19,0.296999990940094,0.296999990940094,0.2759999930858612,0.28600001335144043,163284,0.0,0.0,0.279899999499321,0.29911250099539755,0.37458750009536745,2.1793547206255868,-6.423169019061556,-20.14883013468268,48.716317605607244,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-20,0.28999999165534973,0.31049999594688416,0.2745000123977661,0.3100000023841858,479257,0.0,0.0,0.2828999996185303,0.29861250072717666,0.3726041669646899,9.579357653657775,-5.261836349912851,-19.85798141772395,55.25246933985703,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-24,0.3199999928474426,0.3199999928474426,0.2904999852180481,0.30000001192092896,96916,0.0,0.0,0.28499999940395354,0.2968625009059906,0.3709375003973643,5.263162297665371,-3.995958218311185,-19.969671282095057,52.26354439915896,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-25,0.30000001192092896,0.30000001192092896,0.25999999046325684,0.2750000059604645,662837,0.0,0.0,0.28585000038146974,0.2948625013232231,0.36963750049471855,-3.7956950871176605,-3.056509695640827,-20.229278433983954,45.61941291376839,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-26,0.2750000059604645,0.28850001096725464,0.2605000138282776,0.2759999930858612,112922,0.0,0.0,0.28585000038146974,0.29358750134706496,0.36868750055631,-3.445865762625012,-2.635500806435327,-20.369553916508472,45.91558930752414,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-27,0.2605000138282776,0.29750001430511475,0.25,0.2630000114440918,259845,0.0,0.0,0.28335000276565553,0.29117500185966494,0.36742083405454956,-7.1819273417809635,-2.687386981723368,-20.751635489337737,42.662570447542144,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-28,0.2944999933242798,0.2944999933242798,0.24050000309944153,0.25999999046325684,1340155,0.0,0.0,0.2826500028371811,0.2894000016152859,0.366170834004879,-8.013448486314605,-2.3324114514269763,-20.965851253071175,41.92439522886836,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-01,0.25999999046325684,0.28949999809265137,0.23649999499320984,0.2745000123977661,551455,0.0,0.0,0.28260000348091124,0.2877625018358231,0.36506666739781696,-2.8662388476199223,-1.7940135778556698,-21.175355754338078,46.7226581564136,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-02,0.2745000123977661,0.2784999907016754,0.25699999928474426,0.27000001072883606,330926,0.0,0.0,0.28115000426769254,0.28662500232458116,0.3639750008781751,-3.9658521677418133,-1.9101606672430451,-21.251459129602008,45.467157894090704,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-03,0.25999999046325684,0.2680000066757202,0.24950000643730164,0.2590000033378601,688534,0.0,0.0,0.2773500055074692,0.28531250208616254,0.36262500087420146,-6.616189581836841,-2.790798342334376,-21.32023401631358,42.463373580313004,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-04,0.25850000977516174,0.27799999713897705,0.25,0.27799999713897705,209137,0.0,0.0,0.27655000388622286,0.28476250171661377,0.36113333428899447,0.5243150361157616,-2.8839814866367885,-21.147544499801135,48.76022333621854,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-05,0.27799999713897705,0.36000001430511475,0.27300000190734863,0.3100000023841858,560904,0.0,0.0,0.27655000388622286,0.28553750142455103,0.3598583343128363,12.095461228677038,-3.147571682699963,-20.652803006550855,57.24673964541109,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-08,0.31949999928474426,0.31949999928474426,0.2980000078678131,0.3100000023841858,102458,0.0,0.0,0.2775500029325485,0.2863750018179417,0.3582750009993712,11.691586780319163,-3.0816233363146437,-20.06838294072204,57.24673964541108,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-09,0.3384999930858612,0.4009999930858612,0.28299999237060547,0.33399999141693115,3317507,0.0,0.0,0.2834500014781952,0.2877375014126301,0.35655833408236504,17.833829484959296,-1.49007338750968,-19.3014231028568,62.630328254579375,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-10,0.33399999141693115,0.3345000147819519,0.2809999883174896,0.3100000023841858,2190317,0.0,0.0,0.28685000240802766,0.28852500170469286,0.3547250010073185,8.070420004120685,-0.5805387008989865,-18.662343819757957,55.1513320071616,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-11,0.3100000023841858,0.3700000047683716,0.29100000858306885,0.33899998664855957,1266442,0.0,0.0,0.2944499999284744,0.2898250013589859,0.3533000009755293,15.129898702973982,1.5957900622106238,-17.966317418985764,61.18317513180952,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-12,0.33899998664855957,0.36000001430511475,0.3310000002384186,0.33899998664855957,206009,0.0,0.0,0.3023499995470047,0.291125001013279,0.3521333341797193,12.121708998334924,3.8557315567733443,-17.325350157080933,61.18317513180952,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-15,0.3400000035762787,0.36149999499320984,0.3400000035762787,0.3555000126361847,377804,0.0,0.0,0.31044999957084657,0.29266250133514404,0.35117916762828827,14.511197657469296,6.077819383950756,-16.66290933153592,64.3472701040472,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-16,0.3555000126361847,0.3555000126361847,0.25049999356269836,0.3089999854564667,2006155,0.0,0.0,0.3143499970436096,0.29153750091791153,0.3496875007947286,-1.701928308401011,7.82489252801869,-16.62913308158301,51.58551196888306,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-17,0.3084999918937683,0.3084999918937683,0.28600001335144043,0.2939999997615814,575980,0.0,0.0,0.31784999668598174,0.290862500667572,0.3479708341260751,-7.503538515988345,9.278437734829847,-16.411816123017903,48.260490629959435,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-18,0.2919999957084656,0.3089999854564667,0.2919999957084656,0.3084999918937683,202324,0.0,0.0,0.32089999616146087,0.29150000065565107,0.3462083342174689,-3.86413350452441,10.085761728879037,-15.80214228102697,51.51394799382254,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-19,0.29899999499320984,0.30550000071525574,0.2915000021457672,0.29750001430511475,128470,0.0,0.0,0.31964999735355376,0.2912875011563301,0.3443708342810472,-6.929448844618537,9.736942396990067,-15.414584465476198,48.996852384660805,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-22,0.2994999885559082,0.30300000309944153,0.29100000858306885,0.30300000309944153,136742,0.0,0.0,0.31894999742507935,0.29198750108480453,0.34252916773160297,-5.000782083211785,9.234126885603864,-14.7554344003783,50.30437063550615,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-23,0.2904999852180481,0.30649998784065247,0.28999999165534973,0.29649999737739563,79974,0.0,0.0,0.3151999980211258,0.2922500006854534,0.3408666677772999,-5.932741358227051,7.852864767098254,-14.262663876424972,48.71491167951435,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-24,0.28999999165534973,0.36000001430511475,0.28999999165534973,0.32100000977516174,1425536,0.0,0.0,0.3162999987602234,0.29293750077486036,0.33945833444595336,1.4859345663485934,7.97524998457555,-13.704431133506247,54.544849781974094,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-25,0.3165000081062317,0.32199999690055847,0.30149999260902405,0.3199999928474426,477408,0.0,0.0,0.3143999993801117,0.293775000423193,0.33805833434065186,1.7811684091514555,7.020678725966367,-13.09931731274396,54.27365108090289,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-26,0.3100000023841858,0.3700000047683716,0.3100000023841858,0.3499999940395355,758763,0.0,0.0,0.3155000001192093,0.29503750056028366,0.337233334283034,10.935021840662646,6.935558876436672,-12.512355521573706,60.60220362306672,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-29,0.34950000047683716,0.4000000059604645,0.3310000002384186,0.3790000081062317,654534,0.0,0.0,0.31784999966621397,0.29701250046491623,0.33643333440025647,19.238637251607237,7.0156977126149975,-11.717279444266088,65.5637328347581,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-30,0.3779999911785126,0.3894999921321869,0.35100001096725464,0.36250001192092896,292566,0.0,0.0,0.3232000023126602,0.2987875007092953,0.33549583454926807,12.159656351193442,8.170523045780634,-10.941517020409421,60.86700020010954,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-31,0.3619999885559082,0.3880000114440918,0.3409999907016754,0.3529999852180481,197785,0.0,0.0,0.3291000008583069,0.3006374999880791,0.3344708343346914,7.262225553755405,9.467382103482226,-10.115481194021433,58.27839730901723,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-01,0.36899998784065247,0.36899998784065247,0.3499999940395355,0.3499999940395355,93296,0.0,0.0,0.3332500010728836,0.30265000015497207,0.3334041677415371,5.026254437427173,10.110689212702063,-9.224290084581781,57.44752423393123,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-02,0.34200000762939453,0.34950000047683716,0.33000001311302185,0.3384999930858612,187791,0.0,0.0,0.33734999895095824,0.30411249995231626,0.3325000010430813,0.3408905108875201,10.929343254175182,-8.53759428622887,54.25433877666226,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-05,0.32100000977516174,0.33500000834465027,0.3100000023841858,0.3199999928474426,383702,0.0,0.0,0.33904999792575835,0.30513749942183493,0.3315083342293898,-5.618641850718163,11.113841651117863,-7.954802967127626,49.48873711987635,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-06,0.3199999928474426,0.36000001430511475,0.3174999952316284,0.32899999618530273,23980,0.0,0.0,0.3422999978065491,0.30669999942183496,0.3305666675170263,-3.885481071128384,11.607433469782928,-7.2199257942309165,51.71095921656113,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-07,0.32899999618530273,0.32899999618530273,0.30000001192092896,0.31949999928474426,99526,0.0,0.0,0.34214999675750735,0.307787499576807,0.32972083414594333,-6.619902875175493,11.164357625942287,-6.652092405973968,49.24802112396686,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-08,0.3199999928474426,0.32899999618530273,0.3149999976158142,0.3264999985694885,22767,0.0,0.0,0.3427999973297119,0.3087499998509884,0.32892500087618826,-4.754958835237592,11.02833926968648,-6.13361738130511,51.09631778099515,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-09,0.32850000262260437,0.34950000047683716,0.31150001287460327,0.33000001311302185,216348,0.0,0.0,0.34079999923706056,0.3103250004351139,0.32820000102122626,-3.16901002001653,9.820349233615385,-5.446374323733258,52.036869657055654,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-12,0.33000001311302185,0.36000001430511475,0.33000001311302185,0.3499999940395355,40493,0.0,0.0,0.33789999783039093,0.3122000001370907,0.3275083343187968,3.580940007942288,8.231901884053508,-4.6741815635155515,57.1127754271983,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-13,0.3499999940395355,0.35899999737739563,0.3230000138282776,0.3490000069141388,98731,0.0,0.0,0.3365499973297119,0.31381250023841856,0.32668333426117896,3.699304615423851,7.24556767943233,-3.9398502075010486,56.789166097938775,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-14,0.3400000035762787,0.34150001406669617,0.33000001311302185,0.3395000100135803,17220,0.0,0.0,0.3351999998092651,0.31487500071525576,0.3258958344658216,1.2828192740936697,6.454942135082183,-3.3817043929481865,53.677494591455535,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-15,0.3395000100135803,0.3479999899864197,0.30000001192092896,0.3269999921321869,91862,0.0,0.0,0.3328999996185303,0.3159000001847744,0.32512083450953166,-1.7723062460511283,5.381449643498692,-2.8361253251172243,49.81010798468967,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-16,0.3264999985694885,0.34450000524520874,0.3199999928474426,0.34150001406669617,35875,0.0,0.0,0.3332000017166138,0.31668750047683714,0.324458334594965,2.491000092233351,5.214131032931121,-2.3950175691521394,53.954451194625925,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-19,0.34299999475479126,0.34299999475479126,0.32100000977516174,0.3384999930858612,90441,0.0,0.0,0.3350500017404556,0.31765000000596044,0.32387083445986115,1.029694471715924,5.477727604019735,-1.920776368849502,52.97970994518957,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-20,0.33899998664855957,0.33899998664855957,0.3230000138282776,0.3305000066757202,102988,0.0,0.0,0.33520000278949735,0.31903750002384185,0.32327500109871227,-1.402146800317509,5.066019751423476,-1.3108038235151056,50.36661911524183,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-21,0.3395000100135803,0.35749998688697815,0.32100000977516174,0.33899998664855957,223312,0.0,0.0,0.33715000152587893,0.3206124998629093,0.3226166675488154,0.5487127730410646,5.158096353086952,-0.6212226110738245,53.01810197539976,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-22,0.3400000035762787,0.3499999940395355,0.32749998569488525,0.3474999964237213,369134,0.0,0.0,0.3392500013113022,0.3227249994874001,0.32207916751503946,2.4318334798910697,5.120459168068655,0.20051963538761475,55.573971401530265,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-23,0.35749998688697815,0.35749998688697815,0.3199999928474426,0.32749998569488525,181071,0.0,0.0,0.33899999856948854,0.3244124993681908,0.32142500082651776,-3.3923341956138677,4.4965897521543186,0.9294543156229018,48.84125383697359,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-26,0.32199999690055847,0.3449999988079071,0.32199999690055847,0.33649998903274536,45933,0.0,0.0,0.3376499980688095,0.32596249878406525,0.3208791673183441,-0.34059204579938995,3.5855349398602723,1.5841886864154011,51.678249963127634,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-27,0.33799999952316284,0.3395000100135803,0.3070000112056732,0.3100000023841858,576622,0.0,0.0,0.3337499976158142,0.326962498575449,0.32011250058809915,-7.116103491023082,2.0759258538633047,2.139872068340129,43.949935866263104,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-28,0.3100000023841858,0.32199999690055847,0.3075000047683716,0.30799999833106995,228323,0.0,0.0,0.33059999644756316,0.3281874984502792,0.31918750057617823,-6.836055160114869,0.7350974697926929,2.819658620044562,43.422149474553684,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-29,0.31949999928474426,0.31949999928474426,0.30000001192092896,0.3095000088214874,34766,0.0,0.0,0.32884999811649324,0.328974998742342,0.3184083340068658,-5.884138484364895,-0.0379969986554055,3.31858924749386,43.96565299539362,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-30,0.3100000023841858,0.3190000057220459,0.2800000011920929,0.28999999165534973,262900,0.0,0.0,0.3236999958753586,0.3284749984741211,0.31757500072320305,-10.410875702632111,-1.4536882931559587,3.4322593800191576,38.75376366802404,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-02,0.2904999852180481,0.2944999933242798,0.2605000138282776,0.27900001406669617,523073,0.0,0.0,0.31774999797344206,0.32769999876618383,0.316858334094286,-12.195116964244532,-3.036313954899087,3.421612596332007,36.15039208957091,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-03,0.27000001072883606,0.3100000023841858,0.25,0.26750001311302185,385524,0.0,0.0,0.31144999861717226,0.3260374993085861,0.3158708341419697,-14.111409760567314,-4.474178805305813,3.218614720866235,33.60847250862919,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-04,0.26750001311302185,0.2745000123977661,0.25,0.2630000114440918,298411,0.0,0.0,0.30385000109672544,0.3248624995350838,0.31492083420356115,-13.4441301646169,-6.468120656717745,3.1568776186768432,32.641274520659024,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-05,0.2630000114440918,0.2630000114440918,0.25,0.26249998807907104,171685,0.0,0.0,0.29535000026226044,0.3229499995708466,0.31413333415985106,-11.122401271041047,-8.546214381564488,2.806663429901723,32.52925260324368,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-06,0.2524999976158142,0.26750001311302185,0.24799999594688416,0.2540000081062317,360587,0.0,0.0,0.2880000025033951,0.32082500010728837,0.31328333417574566,-11.805553507508245,-10.231433832437045,2.407298795955735,30.606339858975062,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-09,0.2409999966621399,0.2409999966621399,0.2199999988079071,0.23849999904632568,1425421,0.0,0.0,0.2782000035047531,0.3178999997675419,0.31227916752298673,-14.270310552943302,-12.488202671223227,1.7999382697026778,27.422893721035692,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-10,0.23849999904632568,0.24650000035762787,0.23849999904632568,0.24449999630451202,451655,0.0,0.0,0.27165000289678576,0.316287500038743,0.31127500074605147,-9.994480509020816,-14.112950128123769,1.6103121936158649,30.43906036639298,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-11,0.2485000044107437,0.2485000044107437,0.2304999977350235,0.23549999296665192,41896,0.0,0.0,0.26440000236034394,0.3148249998688698,0.3101791672408581,-10.930411927268045,-16.016833964751452,1.4977900254674956,28.5241655033916,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-12,0.2475000023841858,0.2475000023841858,0.2199999988079071,0.22949999570846558,545434,0.0,0.0,0.25640000104904176,0.31284999996423724,0.3090333337585131,-10.491421696769418,-18.04379060944492,1.2350338260618103,27.291530087015744,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-13,0.22949999570846558,0.2800000011920929,0.22949999570846558,0.25,494682,0.0,0.0,0.25240000188350675,0.31166249960660936,0.3078833336631457,-0.9508723714726653,-19.014959386485597,1.227466877956585,37.26644453886423,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-16,0.24150000512599945,0.25999999046325684,0.2409999966621399,0.2475000023841858,91322,0.0,0.0,0.24925000071525574,0.31027499958872795,0.30672916695475577,-0.7021056473613243,-19.66803608230162,1.1560141701474411,36.606880122577905,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-17,0.2475000023841858,0.24950000643730164,0.23350000381469727,0.2485000044107437,131858,0.0,0.0,0.24734999984502792,0.30907499976456165,0.3056833335508903,0.46493008548061515,-19.970880843339913,1.109535863232376,37.08653496268617,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-18,0.25,0.25999999046325684,0.23999999463558197,0.25949999690055847,369029,0.0,0.0,0.2469999983906746,0.3075374994426966,0.30467916689813135,5.060728174626499,-19.684591687753493,0.9381450571974685,42.26172937119316,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-19,0.25999999046325684,0.34850001335144043,0.2515000104904175,0.27000001072883606,312241,0.0,0.0,0.2477500006556511,0.3062874998897314,0.3037875002870957,8.980831489122927,-19.111945232879172,0.8229435379247199,46.763417437949485,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-20,0.2605000138282776,0.2694999873638153,0.25200000405311584,0.25949999690055847,23036,0.0,0.0,0.24829999953508378,0.304024999961257,0.30294166691601276,4.510671520920475,-18.329084921725006,0.357604503953746,43.14109216855498,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-23,0.25999999046325684,0.26750001311302185,0.25200000405311584,0.26249998807907104,77405,0.0,0.0,0.25069999843835833,0.30111249946057794,0.3022791667530934,4.70681679865031,-16.742081817437036,-0.38595689707865954,44.46471723000062,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-24,0.27000001072883606,0.2750000059604645,0.26249998807907104,0.27000001072883606,10672,0.0,0.0,0.2532499998807907,0.2987999994307756,0.30170833356678484,6.614022055648516,-15.244310454069353,-0.9639555200968422,47.74010186677486,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-25,0.25999999046325684,0.25999999046325684,0.24950000643730164,0.25949999690055847,39583,0.0,0.0,0.2556500002741814,0.2964624997228384,0.3011458336065213,1.5059638655380447,-13.766496432706479,-1.5551714023718437,43.84164988659749,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-26,0.25949999690055847,0.25999999046325684,0.2395000010728836,0.24549999833106995,237164,0.0,0.0,0.2572500005364418,0.2938499998301268,0.3005541668583949,-4.567542149997925,-12.455334121096898,-2.2306019238877477,39.24050186949076,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-27,0.24549999833106995,0.27000001072883606,0.22050000727176666,0.27000001072883606,359308,0.0,0.0,0.25925000160932543,0.2921375002712011,0.30029583362241585,4.146580155363032,-11.25754092896157,-2.7167654152247804,49.27362494355752,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-30,0.27000001072883606,0.27000001072883606,0.24250000715255737,0.2535000145435333,202228,0.0,0.0,0.25985000282526016,0.2904750008136034,0.2998083336899678,-2.4437129931443478,-10.543075274142149,-3.113099880010677,44.00360301047801,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-01,0.2529999911785126,0.2529999911785126,0.23999999463558197,0.24950000643730164,147959,0.0,0.0,0.25995000302791593,0.2884875010699034,0.29935416715840496,-4.020002488513946,-9.892108994722978,-3.630036685860266,42.80827432647788,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-02,0.24950000643730164,0.2694999873638153,0.24050000309944153,0.26899999380111694,417966,0.0,0.0,0.2609000027179718,0.28722500093281267,0.29908750044802823,3.1046343421855287,-9.165287885576078,-3.9662304501009675,49.94652045885256,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-03,0.26649999618530273,0.26649999618530273,0.24549999833106995,0.25450000166893005,75502,0.0,0.0,0.2593500018119812,0.2854250010102987,0.298666667068998,-1.8700598068887662,-9.135499380230073,-4.433593540467045,45.40805212016815,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-04,0.2554999887943268,0.2554999887943268,0.24050000309944153,0.2475000023841858,202288,0.0,0.0,0.2581500023603439,0.2833625007420778,0.2982666670034329,-4.125508378377662,-8.897612886569918,-4.996926545997029,43.359697130544085,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-07,0.23999999463558197,0.24500000476837158,0.23000000417232513,0.23999999463558197,175504,0.0,0.0,0.255900003015995,0.28061250075697897,0.29779583364725115,-6.21336779719351,-8.806627528823421,-5.770172362661864,41.214483192372136,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-08,0.2395000010728836,0.3100000023841858,0.23000000417232513,0.28999999165534973,650532,0.0,0.0,0.2579000011086464,0.2791375003755093,0.2977375003198783,12.446681042541153,-7.608257306271335,-6.2471136233715425,56.62237158493851,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-09,0.28999999165534973,0.2994999885559082,0.25999999046325684,0.27000001072883606,126580,0.0,0.0,0.25895000249147415,0.27740000039339063,0.2975708338121573,4.267236196580352,-6.651044656002846,-6.778498134497818,50.87794561994695,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-10,0.26899999380111694,0.27950000762939453,0.24950000643730164,0.25949999690055847,180418,0.0,0.0,0.260350002348423,0.27571250051259993,0.29690833389759064,-0.32648566936710033,-5.571926603115659,-7.138847571823819,48.117936310439845,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-11,0.28700000047683716,0.28700000047683716,0.24300000071525574,0.25200000405311584,314196,0.0,0.0,0.25855000168085096,0.27347500026226046,0.29625833382209144,-2.5333581841628856,-5.457536728072599,-7.690360391182375,46.19046051151548,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-14,0.2515000104904175,0.2515000104904175,0.20000000298023224,0.20749999582767487,1180087,0.0,0.0,0.25394999980926514,0.27020000033080577,0.29490416708091893,-18.291003747382394,-6.014063842207905,-8.377015148563355,36.77712320560774,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-15,0.2160000056028366,0.2214999943971634,0.1599999964237213,0.19419999420642853,1651601,0.0,0.0,0.24841999858617783,0.2667925000190735,0.29356416712204614,-21.825941827682676,-6.886438498676759,-9.119528233104349,34.51324328439121,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-16,0.1720000058412552,0.19380000233650208,0.1720000058412552,0.17299999296665192,1509062,0.0,0.0,0.23881999850273133,0.2626425001770258,0.2922808337956667,-27.560508311169198,-9.070314841747871,-10.14036166304393,31.21482717071119,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-17,0.21850000321865082,0.21899999678134918,0.17139999568462372,0.1850000023841858,659010,0.0,0.0,0.23186999857425689,0.2585800003260374,0.29082666722436745,-20.213911449635376,-10.329492504487007,-11.087933306147727,35.001463792975755,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-18,0.21250000596046448,0.21250000596046448,0.18039999902248383,0.18400000035762787,723758,0.0,0.0,0.2255199983716011,0.254992500692606,0.28960166722536085,-18.410783218239725,-11.558183962646822,-11.950610251778306,34.8293924006351,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-21,0.18400000035762787,0.23000000417232513,0.17900000512599945,0.1868000030517578,351329,0.0,0.0,0.2201999992132187,0.25125000104308126,0.2883250005543232,-15.16802737547688,-12.358209632221449,-12.858752948916289,35.78136789423753,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-22,0.1868000030517578,0.20649999380111694,0.17900000512599945,0.18559999763965607,939957,0.0,0.0,0.20975999981164933,0.24814000092446803,0.2872425006081661,-11.517926293710602,-15.467075429124902,-13.613061994972202,35.54174835697545,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-23,0.19499999284744263,0.21950000524520874,0.18960000574588776,0.19740000367164612,190054,0.0,0.0,0.20249999910593033,0.24537500105798243,0.2862916671981414,-2.5185162749637064,-17.47325594179852,-14.291951470540255,39.8102140265494,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-24,0.23849999904632568,0.23849999904632568,0.18219999969005585,0.18799999356269836,126586,0.0,0.0,0.19534999877214432,0.24233750067651272,0.28535833371182284,-3.762480294673039,-19.389282208984344,-15.076073817684934,37.67017504510106,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-25,0.18799999356269836,0.19519999623298645,0.18119999766349792,0.19179999828338623,168683,0.0,0.0,0.18932999819517135,0.23988250084221363,0.28463166691362857,1.3046004921357859,-21.07386010632512,-15.721780558237766,39.095510146275565,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-28,0.19580000638961792,0.19580000638961792,0.17900000512599945,0.1834000051021576,228481,0.0,0.0,0.18691999912261964,0.23749250061810018,0.28385583373407525,-1.88315538036833,-21.29435723816966,-16.333408584940216,37.07711370048422,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-29,0.18400000035762787,0.19979999959468842,0.17900000512599945,0.18940000236034393,689286,0.0,0.0,0.18643999993801116,0.2355400003492832,0.2831050003568331,1.5876434366643055,-20.84571637023922,-16.801186820295545,39.48054332764885,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-30,0.18940000236034393,0.18940000236034393,0.17900000512599945,0.18119999766349792,229953,0.0,0.0,0.18726000040769578,0.23349500000476836,0.282294167081515,-3.2361437204978265,-19.801280368371224,-17.286636695775382,37.37918399279216,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-31,0.18000000715255737,0.19140000641345978,0.16040000319480896,0.1712000072002411,495210,0.0,0.0,0.1858800008893013,0.23121250048279762,0.28132916713754336,-7.897564890696715,-19.606422446380275,-17.814244845165103,34.93702837958577,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-01,0.1785999983549118,0.1785999983549118,0.15520000457763672,0.16920000314712524,639445,0.0,0.0,0.18440000116825103,0.22909250035881995,0.2803475004931291,-8.242948983095147,-19.508495092841777,-18.282667062895875,34.45221275133491,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-04,0.17520000040531158,0.17520000040531158,0.15919999778270721,0.17000000178813934,1136942,0.0,0.0,0.18272000104188918,0.2273800004273653,0.2793141671766837,-6.961470655220571,-19.64112907975053,-18.593459570730186,34.84170909888624,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-05,0.1679999977350235,0.18400000035762787,0.1454000025987625,0.16200000047683716,874270,0.0,0.0,0.1803600013256073,0.22531750053167343,0.27771416716277597,-10.179641114342473,-19.952954874779614,-18.86712052410038,32.74618999859226,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-06,0.17960000038146973,0.17960000038146973,0.14059999585151672,0.1687999963760376,434417,0.0,0.0,0.17750000059604645,0.22365000061690807,0.2764458337177833,-4.901410811715025,-20.634920587329812,-19.098075160276494,36.25562586847803,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-07,0.1509999930858612,0.1671999990940094,0.1509999930858612,0.1664000004529953,208000,0.0,0.0,0.17534000128507615,0.22207250073552132,0.2754741671184699,-5.098665887167282,-21.043802945282962,-19.385362679028542,35.55052225599346,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-08,0.15600000321865082,0.1664000004529953,0.14000000059604645,0.15520000457763672,427827,0.0,0.0,0.1716800019145012,0.21970250084996223,0.2742175005376339,-9.599252768573315,-21.857966454490313,-19.880204429253762,32.38521176955513,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-11,0.15360000729560852,0.17000000178813934,0.12399999797344208,0.1518000066280365,633557,0.0,0.0,0.1685200020670891,0.2173100009560585,0.2731908338765303,-9.921668190103766,-22.45179636202527,-20.45487109780827,31.469199065556964,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-12,0.15880000591278076,0.15880000591278076,0.13699999451637268,0.14000000059604645,107287,0.0,0.0,0.16358000189065933,0.21459750086069107,0.2719741671035687,-14.414965779480978,-23.773575538118898,-21.096366193127597,28.460457472740046,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-13,0.15279999375343323,0.15279999375343323,0.1242000013589859,0.13279999792575836,337574,0.0,0.0,0.15874000191688536,0.21143000088632108,0.27063500036795934,-16.34118916333951,-24.920776970419343,-21.876327674226275,26.778115347574982,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-14,0.12999999523162842,0.13860000669956207,0.11500000208616257,0.12999999523162842,372417,0.0,0.0,0.1546200007200241,0.20793000049889088,0.26933083360393845,-15.922911249351241,-25.638435844254776,-22.79755061217384,26.13120753334063,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-15,0.12020000070333481,0.13600000739097595,0.12020000070333481,0.1242000013589859,287003,0.0,0.0,0.15012000054121016,0.20454750061035157,0.2678700003772974,-17.266186443363914,-26.608733867064906,-23.63926519496603,24.794981447548395,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-18,0.12520000338554382,0.13979999721050262,0.12520000338554382,0.13580000400543213,80131,0.0,0.0,0.14670000076293946,0.20138000100851058,0.2665016669780016,-7.430127267089269,-27.152646723474927,-24.435744326832477,32.256130303360194,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-19,0.13860000669956207,0.13860000669956207,0.13580000400543213,0.1371999979019165,17542,0.0,0.0,0.1442200005054474,0.1980600006878376,0.26521583360930284,-4.867565232927408,-27.183681710295176,-25.321200475682932,33.11854731920616,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-20,0.13779999315738678,0.13779999315738678,0.12600000202655792,0.12919999659061432,121110,0.0,0.0,0.14026000052690507,0.194802500680089,0.2639675001303355,-7.885358544661628,-27.998870631930643,-26.202089051150562,30.712464446124557,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-21,0.12999999523162842,0.17980000376701355,0.1120000034570694,0.16940000653266907,1410552,0.0,0.0,0.14056000113487244,0.19290000088512899,0.2631333336234093,20.51793196140031,-27.133229398700088,-26.69115758583317,50.26561810559628,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-22,0.18199999630451202,0.18199999630451202,0.1451999992132187,0.16459999978542328,489480,0.0,0.0,0.1415000006556511,0.19026500061154367,0.26217166694502037,16.32508764857707,-25.63004220384919,-27.427321636764106,48.50545602199711,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-25,0.16459999978542328,0.1793999969959259,0.1501999944448471,0.17139999568462372,99271,0.0,0.0,0.1434599995613098,0.1882125001400709,0.26127500012516974,19.475809430330667,-23.777645239001412,-27.96383119322422,51.1169636259565,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-26,0.17980000376701355,0.17980000376701355,0.1624000072479248,0.17419999837875366,306575,0.0,0.0,0.14687999933958054,0.18632999993860722,0.26050583347678186,18.60021729439854,-21.172114319768596,-28.473770643906033,52.192101627526355,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-27,0.17419999837875366,0.17419999837875366,0.1599999964237213,0.16840000450611115,95167,0.0,0.0,0.15043999999761581,0.18381500020623207,0.2596091669052839,11.938317275179449,-18.156842570612312,-29.195489359089027,49.75112986555763,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-28,0.15139999985694885,0.17919999361038208,0.15139999985694885,0.16500000655651093,277494,0.0,0.0,0.15394000113010406,0.1815775003284216,0.2585841670632362,7.184620855666607,-15.22077302987938,-29.780116706056027,48.32434099087203,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-29,0.16500000655651093,0.17919999361038208,0.15479999780654907,0.17479999363422394,423496,0.0,0.0,0.15900000035762787,0.17976000010967255,0.2578158337622881,9.93710266733221,-11.54873149720677,-30.275810648846637,52.548482003729056,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-02,0.15539999306201935,0.20999999344348907,0.15539999306201935,0.17020000517368317,445209,0.0,0.0,0.16244000047445298,0.17801500037312507,0.25694250042239825,4.77715136454374,-8.749262627321515,-30.717962158662367,50.463300065815375,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-03,0.19979999959468842,0.19979999959468842,0.17020000517368317,0.17020000517368317,688280,0.0,0.0,0.16574000120162963,0.17502000071108342,0.2559900004416704,2.6909641243623246,-5.302250869472271,-31.630141642597764,50.463300065815375,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-04,0.17020000517368317,0.18639999628067017,0.1632000058889389,0.1793999969959259,434700,0.0,0.0,0.17076000124216079,0.17275500036776065,0.2550100004921357,5.0597304350639085,-1.1548141132545566,-32.255597806216905,54.6384469645969,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-05,0.1793999969959259,0.1793999969959259,0.16040000319480896,0.16940000653266907,89014,0.0,0.0,0.17076000124216079,0.17050250060856342,0.25403833376864593,-0.796436343170941,0.1510245495979723,-32.883160553304144,49.73189374130551,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-06,0.1615999937057495,0.18000000715255737,0.1615999937057495,0.17059999704360962,129498,0.0,0.0,0.17136000096797943,0.16846750043332576,0.25287666705747447,-0.44351302525484193,1.7169486857783811,-33.37957890949424,50.30855752988569,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-09,0.16599999368190765,0.20999999344348907,0.15080000460147858,0.20000000298023224,984422,0.0,0.0,0.1742200016975403,0.1682800006121397,0.2520433336496353,14.797383211744005,3.5298318658147574,-33.233703040102924,61.85446670910625,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-10,0.20999999344348907,0.20999999344348907,0.17720000445842743,0.19380000233650208,698862,0.0,0.0,0.17618000209331514,0.16827000081539153,0.25136666695276894,10.001135221836567,4.700779247396354,-33.05794962583127,58.7540956182857,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-11,0.19460000097751617,0.19480000436306,0.17800000309944153,0.19280000030994415,668298,0.0,0.0,0.17862000167369843,0.16876500099897385,0.25067333367963635,7.938639851851321,5.839481300263499,-32.67532747832778,58.246976680774424,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-12,0.17900000512599945,0.19480000436306,0.17739999294281006,0.1850000023841858,222356,0.0,0.0,0.1806200012564659,0.16876500099897385,0.2500233336041371,2.4249812297922837,7.024560890776248,-32.50029964556023,54.309434203202464,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-13,0.1850000023841858,0.1940000057220459,0.17180000245571136,0.1940000057220459,73901,0.0,0.0,0.1825400024652481,0.1690150011330843,0.24947333373129368,6.278077737497322,8.002249055700132,-32.251275675367616,57.85007249901658,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-16,0.18199999630451202,0.19900000095367432,0.18199999630451202,0.19840000569820404,1044990,0.0,0.0,0.18536000251770018,0.16930500119924546,0.24883916700879732,7.034960619003367,9.482886627525254,-31.962076856952365,59.5023373776951,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-17,0.19840000569820404,0.19840000569820404,0.15000000596046448,0.17900000512599945,1160094,0.0,0.0,0.18624000251293182,0.16914000138640403,0.2480808336287737,-3.887455589155533,10.109968656948551,-31.820609068291077,50.165102286810935,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-18,0.17880000174045563,0.17880000174045563,0.15000000596046448,0.17059999704360962,677392,0.0,0.0,0.18536000251770018,0.16847000122070313,0.24734416690965494,-7.962885883474844,10.025524529361407,-31.88842764089174,46.74468458278218,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-19,0.1501999944448471,0.16419999301433563,0.15000000596046448,0.1597999930381775,119430,0.0,0.0,0.18440000116825103,0.1677650012075901,0.2463591668754816,-13.340568315738729,9.915655733270018,-31.90226962718042,42.712322464039744,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-20,0.15960000455379486,0.15960000455379486,0.13120000064373016,0.13779999315738678,841374,0.0,0.0,0.18112000077962875,0.16641500107944013,0.2449241667985916,-23.917848628407437,8.836342640270166,-32.054479043593886,35.91567464778839,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-23,0.13040000200271606,0.15119999647140503,0.12999999523162842,0.13619999587535858,538198,0.0,0.0,0.1747400000691414,0.16523500084877013,0.24347583341101806,-22.055627892030014,5.752412728263686,-32.134948042324794,35.473567339126106,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-27,0.13699999451637268,0.1387999951839447,0.09399999678134918,0.11259999871253967,3551941,0.0,0.0,0.16661999970674515,0.16331500075757505,0.2416308334718148,-32.42107855556468,2.0236958845415867,-32.41135727132893,29.671748161534538,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-30,0.11159999668598175,0.11540000140666962,0.09480000287294388,0.11540000140666962,1625707,0.0,0.0,0.1588799998164177,0.16167000085115432,0.24000916679700215,-27.36656499243974,-1.725738244601918,-32.64007245694348,31.111336323058126,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-02,0.10999999940395355,0.12060000002384186,0.10000000149011612,0.11879999935626984,392846,0.0,0.0,0.1522599995136261,0.16036000065505504,0.23817416690289975,-21.975568280730123,-5.051135637528828,-32.67111931562605,32.907263970806525,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-03,0.11999999731779099,0.12759999930858612,0.10019999742507935,0.11940000206232071,352196,0.0,0.0,0.14479999914765357,0.15911500062793493,0.23634416703134775,-17.541434554452106,-8.996638546829857,-32.67656967102956,33.23803648511439,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-07,0.11900000274181366,0.11900000274181366,0.09809999912977219,0.1103999987244606,1473971,0.0,0.0,0.13599999845027924,0.15762500055134296,0.2343016669154167,-18.823529424654986,-13.719271705264696,-32.72561709591002,30.78623848794662,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-08,0.11100000143051147,0.11339999735355377,0.0989999994635582,0.10019999742507935,240260,0.0,0.0,0.12811999768018723,0.15608000047504902,0.23256166701515515,-21.79207052813231,-17.91389204879679,-32.886617782595316,28.2434549697942,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-09,0.10019999742507935,0.10819999873638153,0.09040000289678574,0.10000000149011612,772333,0.0,0.0,0.12105999812483788,0.15436000060290098,0.23094500036289295,-17.3963298867761,-21.572947880279596,-33.16157511080602,28.194282792977674,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-10,0.10000000149011612,0.10559999942779541,0.09799999743700027,0.10559999942779541,721867,0.0,0.0,0.11563999876379967,0.15284000057727098,0.22925416709234317,-8.68211643318282,-24.33917932018339,-33.33163688330808,31.77599122286057,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-13,0.09709999710321426,0.11680000275373459,0.09650000184774399,0.10580000281333923,433097,0.0,0.0,0.11243999972939492,0.15160500053316356,0.22765666699657838,-5.905369025289856,-25.83358112597434,-33.40629882126749,31.906629426581375,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-14,0.09510000050067902,0.14480000734329224,0.09510000050067902,0.12479999661445618,1699039,0.0,0.0,0.11129999980330467,0.15093000028282405,0.22617166694253682,12.129377210251056,-26.257205595479817,-33.2675032539904,43.06096838538814,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-15,0.1340000033378601,0.1340000033378601,0.11079999804496765,0.12120000272989273,232226,0.0,0.0,0.11216000020503998,0.15046000033617019,0.22471083365380765,8.059916644371166,-25.455270534066976,-33.04283648025143,41.66820672537315,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-16,0.13300000131130219,0.133200004696846,0.12020000070333481,0.13300000131130219,492620,0.0,0.0,0.11392000019550323,0.1504650004208088,0.22314416691660882,16.74859645633331,-24.288040489880935,-32.570498032763254,47.6455906403397,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-17,0.13300000131130219,0.1446000039577484,0.12999999523162842,0.13979999721050262,479685,0.0,0.0,0.11601999998092652,0.15071000047028066,0.22164250028630098,20.496463742014733,-23.017716396460933,-32.003112997008735,50.7759523598556,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-20,0.1316000074148178,0.14480000734329224,0.12559999525547028,0.1436000019311905,187935,0.0,0.0,0.11843999996781349,0.15119500048458576,0.21992250035206476,21.242825033953334,-21.66407646535351,-31.250781415023937,52.485676252520854,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-21,0.12700000405311584,0.14480000734329224,0.1128000020980835,0.14480000734329224,823993,0.0,0.0,0.12188000082969666,0.15142000056803226,0.21797083367904027,18.805387559540453,-19.508651187108814,-30.531989985872794,53.04037480475031,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-22,0.14480000734329224,0.20000000298023224,0.14480000734329224,0.1648000031709671,1386865,0.0,0.0,0.12834000140428542,0.15211000069975852,0.21632333360612394,28.408914888374188,-15.62684845580363,-29.683960502977193,61.175585085555355,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-23,0.17000000178813934,0.17900000512599945,0.16220000386238098,0.17720000445842743,442306,0.0,0.0,0.13606000170111657,0.15331000089645386,0.2148583337664604,30.236661945428484,-11.251711626424164,-28.646006785525163,65.20080711634662,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-24,0.17720000445842743,0.1785999983549118,0.164000004529953,0.17219999432563782,714994,0.0,0.0,0.1427200011909008,0.15338000059127807,0.21337666710217792,20.655824613751843,-6.950058260061997,-28.11772595649821,62.39184063448793,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-27,0.17219999432563782,0.17219999432563782,0.1599999964237213,0.17000000178813934,161292,0.0,0.0,0.14914000108838082,0.153515000641346,0.21197250050803026,13.986858352908834,-2.8498840730140684,-27.57786964185465,61.14365272455739,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-28,0.1679999977350235,0.18479999899864197,0.15680000185966492,0.17479999363422394,96549,0.0,0.0,0.15414000079035758,0.153600000590086,0.21076250051458675,13.403394795595954,0.35156262903454943,-27.12176017315024,62.888144082589385,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-29,0.17479999363422394,0.17479999363422394,0.16019999980926514,0.16979999840259552,122549,0.0,0.0,0.15900000035762787,0.15349000059068202,0.20943583386639755,6.792451585330783,3.589810245450187,-26.712636630942665,59.87271197646462,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-30,0.16979999840259552,0.17839999496936798,0.15860000252723694,0.17640000581741333,221200,0.0,0.0,0.163340000808239,0.15369000062346458,0.20824333392083644,7.99559504380484,6.278873150906279,-26.19691697699686,62.433320035491356,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-31,0.17599999904632568,0.17599999904632568,0.15919999778270721,0.1695999950170517,338453,0.0,0.0,0.1663200005888939,0.1538050003349781,0.2069358338912328,1.9720986150458315,8.13692677524065,-25.675028126922044,58.30512779852628,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-03,0.1599999964237213,0.17479999363422394,0.15000000596046448,0.17260000109672546,301661,0.0,0.0,0.1692200005054474,0.15375000052154064,0.20562416712443035,1.9974001779826671,10.061788573288084,-25.22766040992586,59.57508706580321,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-04,0.1720000058412552,0.1720000058412552,0.149399995803833,0.15539999306201935,234488,0.0,0.0,0.1702799990773201,0.15338000021874904,0.2040025004496177,-8.738551853376569,11.018384948799364,-24.81464693780597,50.14481218784537,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-05,0.1777999997138977,0.1777999997138977,0.1387999951839447,0.14920000731945038,209858,0.0,0.0,0.16871999949216843,0.15285500027239324,0.2023375004529953,-11.569459596652095,10.379116935332947,-24.455427229169153,47.24190095827661,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-06,0.1469999998807907,0.14880000054836273,0.1257999986410141,0.1395999938249588,130356,0.0,0.0,0.16495999842882156,0.15186000019311904,0.20067166698475677,-15.373426797651991,8.626365217333966,-24.32414477094343,43.082991779138396,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-07,0.13899999856948853,0.1597999930381775,0.12880000472068787,0.14239999651908875,374261,0.0,0.0,0.16197999864816665,0.15118499994277954,0.19913333368798097,-12.087913503201845,7.14025776993273,-24.078507027020883,44.6145003744673,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-10,0.14000000059604645,0.1459999978542328,0.11540000140666962,0.13699999451637268,273865,0.0,0.0,0.15867999792099,0.15034499987959862,0.19742916685839493,-13.662719743298856,5.5439143623441565,-23.848637832001383,42.25316962313782,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-11,0.1242000013589859,0.13920000195503235,0.12399999797344208,0.13300000131130219,41466,0.0,0.0,0.15449999868869782,0.14866999983787538,0.19571666692694029,-13.915856025808775,3.921435970390837,-24.038150571319054,40.54145963093502,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-12,0.149399995803833,0.18000000715255737,0.1404000073671341,0.16580000519752502,1577070,0.0,0.0,0.15409999936819077,0.14796999990940093,0.194344166914622,7.592476234460882,4.142731271570665,-23.86187748335861,56.20778468020754,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-13,0.16539999842643738,0.16539999842643738,0.14000000059604645,0.15459999442100525,848226,0.0,0.0,0.15191999822854996,0.14701499976217747,0.1928075003127257,1.764083875529987,3.336393207704782,-23.750373028162656,51.24283066426313,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-14,0.15440000593662262,0.16120000183582306,0.12999999523162842,0.16120000183582306,646479,0.0,0.0,0.1510799989104271,0.1464199997484684,0.19125500035782655,6.698439898319009,3.1826247575221975,-23.44252465319839,53.83092781757206,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-17,0.15000000596046448,0.1597999930381775,0.13199999928474426,0.1444000005722046,390146,0.0,0.0,0.148259998857975,0.14517999961972236,0.18972916714847088,-2.6035331954022736,2.1215038203059957,-23.480400087292306,46.99299554345574,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-18,0.17139999568462372,0.17139999568462372,0.13300000131130219,0.14000000059604645,127291,0.0,0.0,0.14671999961137772,0.14371999949216843,0.18809166724483173,-4.58015201276633,2.087392241726775,-23.590448424760034,45.36757213004481,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-19,0.14000000059604645,0.1518000066280365,0.12520000338554382,0.14139999449253082,167708,0.0,0.0,0.14593999832868576,0.14277999922633172,0.18668666717906793,-3.1108701439957196,2.213194508668457,-23.518909312694188,46.00749118277716,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-20,0.12999999523162842,0.1395999938249588,0.1265999972820282,0.13300000131130219,479845,0.0,0.0,0.1452799990773201,0.14183999933302402,0.18522833387056986,-8.45264168778134,2.425267738629457,-23.424242733762252,42.770397273090225,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-21,0.13500000536441803,0.1363999992609024,0.12020000070333481,0.1265999972820282,271551,0.0,0.0,0.14369999915361403,0.1410099994391203,0.18370416710774104,-11.899792604247745,1.9076659280855623,-23.240718128936592,40.43596867057465,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-24,0.1265999972820282,0.14059999585151672,0.1265999972820282,0.13040000200271606,44525,0.0,0.0,0.1430399999022484,0.14082499966025352,0.1823741671939691,-8.836687575622433,1.5728743101996439,-22.78237547180945,42.444652413569365,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-25,0.1469999998807907,0.1469999998807907,0.11580000072717667,0.12999999523162842,370770,0.0,0.0,0.142739999294281,0.14066999964416027,0.18113250037034354,-8.925321651702584,1.4715288656835206,-22.338619874099695,42.28300779728204,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-26,0.12999999523162842,0.12999999523162842,0.11999999731779099,0.12600000202655792,103793,0.0,0.0,0.1387599989771843,0.14100499972701072,0.17995333361128965,-9.19573151101309,-1.5921426574751243,-21.64357453272288,40.61720019110402,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-27,0.12880000472068787,0.12880000472068787,0.09989999979734421,0.10939999669790268,2128882,0.0,0.0,0.13423999920487403,0.14085499960929154,0.17867333348840475,-18.504173610028936,-4.696319209659881,-21.16618811590454,34.536293359328795,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-28,0.10939999669790268,0.12680000066757202,0.10000000149011612,0.11020000278949738,688161,0.0,0.0,0.12913999930024148,0.14063999969512225,0.17740416694432498,-14.666251055732108,-8.176905873016455,-20.723395556283908,35.04103278270851,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-03,0.10999999940395355,0.10999999940395355,0.0949999988079071,0.1088000014424324,733995,0.0,0.0,0.12557999938726425,0.14037499967962502,0.1761941668887933,-13.361998747177564,-10.539626234106574,-20.329371761651963,34.53915475396744,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-04,0.10859999805688858,0.11959999799728394,0.10000000149011612,0.10000000149011612,1214737,0.0,0.0,0.12157999947667122,0.14011499974876643,0.17504000024249156,-17.749628293670025,-13.228419730456723,-19.952582521333294,31.486455893409584,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-05,0.10000000149011612,0.1151999980211258,0.08569999784231186,0.10620000213384628,278394,0.0,0.0,0.11806000024080276,0.1402649998664856,0.17388750029106934,-10.045737830565871,-15.830748687711951,-19.335777654117294,35.792251857462745,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-06,0.10620000213384628,0.14980000257492065,0.10000000149011612,0.13979999721050262,2107025,0.0,0.0,0.11873999983072281,0.14125999975949527,0.17309000032643476,17.73622823800169,-15.942234154831011,-18.38927754746692,53.022719000711774,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-07,0.13979999721050262,0.14480000734329224,0.12999999523162842,0.14000000059604645,1400252,0.0,0.0,0.12008000016212464,0.14211999978870155,0.1723441670338313,16.5889410451591,-15.508021150679085,-17.537099029987317,53.1033930492083,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-10,0.1469999998807907,0.17000000178813934,0.1469999998807907,0.16979999840259552,1396988,0.0,0.0,0.12401999980211258,0.14371999967843294,0.17167583368718625,36.913399994783035,-13.707208405509483,-16.284082277819113,63.23437417840237,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-11,0.16979999840259552,0.17880000174045563,0.16979999840259552,0.1770000010728836,2572099,0.0,0.0,0.1287200003862381,0.14502499978989364,0.17108833367625872,37.50776922139234,-11.242888762128986,-15.233846356633137,65.19097850015987,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-12,0.1770000010728836,0.1785999983549118,0.1597999930381775,0.17800000309944153,1080362,0.0,0.0,0.13392000049352645,0.14644499979913234,0.1705008336653312,32.91517506232824,-8.552698503045846,-14.108924483863246,65.46587072858587,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-13,0.1777999997138977,0.1777999997138977,0.1599999964237213,0.17399999499320984,391166,0.0,0.0,0.14038000032305717,0.14746999964118004,0.16978833364943663,23.94927667244822,-4.807757059316517,-13.144798307719677,63.312087673866486,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-14,0.17399999499320984,0.17880000174045563,0.16200000047683716,0.17499999701976776,506103,0.0,0.0,0.1468599997460842,0.14834999963641166,0.16899666686852774,19.161103991785794,-1.0043814586985214,-12.217203815136967,63.63419816281618,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-17,0.17299999296665192,0.2800000011920929,0.17000000178813934,0.24400000274181366,3411208,0.0,0.0,0.16037999987602233,0.15085999965667723,0.16886750025053818,52.138672484369394,6.3104867035731385,-10.663686361878003,77.99214845321151,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-18,0.24400000274181366,0.24400000274181366,0.1809999942779541,0.24150000512599945,2418006,0.0,0.0,0.17453000023961068,0.15327749960124493,0.16869250039259592,38.371629401504755,13.8653753444926,-9.137928927175695,76.80887309059997,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-19,0.24150000512599945,0.24150000512599945,0.2004999965429306,0.2329999953508377,519545,0.0,0.0,0.18720999956130982,0.15498249940574169,0.1683841669311126,24.45916131447456,20.79428340563605,-7.958983180914898,72.7665481103662,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-20,0.273499995470047,0.3255000114440918,0.2345000058412552,0.30000001192092896,5542600,0.0,0.0,0.20323000103235245,0.15805249959230422,0.16872166705628236,47.6160066904549,28.583857614769403,-6.32353132239922,81.17605653801839,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-21,0.32199999690055847,0.3695000112056732,0.27000001072883606,0.2750000059604645,2745718,0.0,0.0,0.21673000156879424,0.1606224998831749,0.16896750045319398,26.885989004699113,34.93128405200259,-4.938819919592019,72.21525695422766,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-24,0.2800000011920929,0.3100000023841858,0.2800000011920929,0.2919999957084656,1123268,0.0,0.0,0.22895000129938126,0.16367249973118306,0.16915083366135755,27.538761323979394,39.882999083786494,-3.238727123947967,74.29331697591311,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-25,0.30000001192092896,0.3095000088214874,0.29499998688697815,0.29899999499320984,877529,0.0,0.0,0.24115000069141387,0.1667774997651577,0.16953000016510486,23.989215897130915,44.59384571119088,-1.6236066756718552,75.11852206120741,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-26,0.2985000014305115,0.33000001311302185,0.20900000631809235,0.2874999940395355,3671991,0.0,0.0,0.2520999997854233,0.1697199996560812,0.1698466667284568,14.042044539564927,48.538769912960205,-0.07457730835431237,71.08153625316002,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-27,0.2874999940395355,0.32749998569488525,0.11500000208616257,0.15000000596046448,8432369,0.0,0.0,0.24970000088214875,0.16905999965965748,0.16885500016311805,-39.927911321369926,47.69904257945782,0.12140564172893752,42.01061895437578,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-28,0.14980000257492065,0.14980000257492065,0.10599999874830246,0.1289999932050705,3616043,0.0,0.0,0.245100000500679,0.16804499961435795,0.16780916675925256,-47.368423932454,45.853789796276324,0.14053633639915045,39.36279309671962,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-31,0.125,0.12939999997615814,0.10000000149011612,0.11760000139474869,2720374,0.0,0.0,0.23246000036597253,0.16666999962180853,0.16672666675100725,-49.410650774496446,39.473211071847544,-0.033988041806980576,37.96394256981136,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-01,0.11500000208616257,0.11739999800920486,0.10939999669790268,0.11580000072717667,544332,0.0,0.0,0.21988999992609023,0.16567999981343745,0.16569166680177053,-47.33730466774317,32.71970073255402,-0.007041385096954608,37.73591200442418,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-02,0.1120000034570694,0.11420000344514847,0.10599999874830246,0.11339999735355377,1004504,0.0,0.0,0.20793000012636184,0.16478499956429005,0.1642200001825889,-45.46241654179816,26.182601982068753,0.34405028685480193,37.41323288507867,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-03,0.1136000007390976,0.1340000033378601,0.10000000149011612,0.11819999665021896,942358,0.0,0.0,0.18974999859929084,0.16424999963492154,0.16295500006526709,-37.70751118695359,15.525113559237838,0.794697658332532,38.545077202697364,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-04,0.12600000202655792,0.133200004696846,0.11860000342130661,0.12639999389648438,756121,0.0,0.0,0.17488999739289285,0.16384999956935645,0.16184583337356648,-27.726001612016148,6.737868692433689,1.2383180672708627,40.52388663877761,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-07,0.12600000202655792,0.1289999932050705,0.10100000351667404,0.1185000017285347,625613,0.0,0.0,0.15753999799489976,0.1633874997496605,0.16073333335419496,-24.78100594341061,-3.5789162351588537,1.6512856045962567,39.213847156989445,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-08,0.12250000238418579,0.12250000238418579,0.10849999636411667,0.11749999970197678,220618,0.0,0.0,0.13938999846577643,0.16299999970942736,0.1599833333864808,-15.704138750797226,-14.484663365484291,1.8856128692224632,39.041794270073616,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-09,0.11699999868869781,0.11949999630451202,0.11050000041723251,0.1185000017285347,183059,0.0,0.0,0.12248999923467636,0.1618174996227026,0.15935250011583169,-3.257406752446215,-24.303613935280875,1.5468847398560546,39.32847079877004,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-10,0.12250000238418579,0.1315000057220459,0.11749999970197678,0.1185000017285347,535131,0.0,0.0,0.11933999881148338,0.16091499980539084,0.15889833352218072,-0.7038688547966172,-25.83662246787925,1.2691550870976345,39.32847079877004,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-11,0.125,0.13699999451637268,0.11599999666213989,0.12399999797344208,637014,0.0,0.0,0.11883999928832054,0.15998499970883132,0.15839000015209118,4.34197131943997,-25.718036375531234,1.007007737362567,41.09548257446338,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-14,0.12999999523162842,0.1340000033378601,0.11349999904632568,0.12700000405311584,469829,0.0,0.0,0.11977999955415726,0.1595499997958541,0.15791500018288693,6.027721260504878,-24.92635555787087,1.035366881596824,42.08626995196449,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-15,0.1145000010728836,0.11949999630451202,0.10499999672174454,0.11900000274181366,336935,0.0,0.0,0.12009999975562095,0.15902499984949828,0.15735000018030404,-0.9159009292635837,-24.47728352819749,1.0645056671591302,40.14700298558077,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-16,0.1185000017285347,0.1289999932050705,0.11050000041723251,0.125,393014,0.0,0.0,0.12126000002026557,0.158614999987185,0.15684500019997358,3.0842816914970963,-23.55073604005766,1.1285025247567486,42.294631011309946,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-17,0.12449999898672104,0.12449999898672104,0.10249999910593033,0.11999999731779099,54265,0.0,0.0,0.12144000008702278,0.1582899998873472,0.1562000001470248,-1.1857730304676435,-23.28005548458529,1.3380280015078045,40.97516637357994,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-22,0.11900000274181366,0.13699999451637268,0.11900000274181366,0.12049999833106995,120869,0.0,0.0,0.12085000053048134,0.15813749991357326,0.15563750018676123,-0.28961704416634493,-23.579163325252154,1.6062965055414606,41.172806886554405,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-23,0.09247799962759018,0.09861800074577332,0.08442000299692154,0.08864100277423859,162323,0.0,0.0,0.11786410063505173,0.15709352493286133,0.15477784189085167,-24.79389203613238,-24.9720186204845,1.4961334346828943,33.48017719373634,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-24,0.09746699780225754,0.09746699780225754,0.08365300297737122,0.09017600119113922,152084,0.0,0.0,0.11513170078396798,0.1560979250818491,0.15400097519159317,-21.675784708205946,-26.243926225413126,1.3616471503814285,34.118861118964944,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-25,0.09861800074577332,0.09861800074577332,0.08250200003385544,0.08403600007295609,496756,0.0,0.0,0.11168530061841012,0.15504882503300904,0.15312294183919828,-24.756436516137505,-27.96765754617429,1.2577365420742923,32.76375360040676,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-28,0.08403600007295609,0.09209500253200531,0.08019900321960449,0.08902499824762344,609855,0.0,0.0,0.10873780027031898,0.15453945007175207,0.152354816844066,-18.12874821238805,-29.637513127015502,1.4339114922254406,35.022019197646884,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-29,0.08825699985027313,0.09823399782180786,0.08825699985027313,0.09209500253200531,432118,0.0,0.0,0.10554730072617531,0.15408682506531476,0.1516956084718307,-12.745279227054535,-31.50141118071865,1.576325522915918,36.43679513461935,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-30,0.09209500253200531,0.10092099756002426,0.09209500253200531,0.10092099756002426,456986,0.0,0.0,0.10293940007686615,0.15388984996825456,0.15112661675860484,-1.9607677092879157,-33.108388826097894,1.8284225961753924,40.45104999227072,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-02,0.12150000035762787,0.12150000035762787,0.10050000250339508,0.10300000011920929,1948436,0.0,0.0,0.10133939981460571,0.1539648499339819,0.15056828341136377,1.6386522000737562,-34.18017173526379,2.2558313382231105,41.390009438840345,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-05,0.1014999970793724,0.10649999976158142,0.09600000083446503,0.09799999743700027,703299,0.0,0.0,0.09863939955830574,0.15375984981656074,0.15003495005269846,-0.648221830392948,-35.848402768352756,2.4826880420554973,39.76601443093451,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-06,0.0997999981045723,0.10499999672174454,0.09120000153779984,0.0949999988079071,175668,0.0,0.0,0.09613939970731736,0.15263984985649587,0.14941995007296402,-1.1851549966808574,-37.01553048060341,2.1549329804751793,38.78276559233848,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-07,0.09640000015497208,0.09640000015497208,0.08579999953508377,0.09220000356435776,1777848,0.0,0.0,0.09330940023064613,0.15144484993070365,0.14880161676555873,-1.1889441616237129,-38.38720810028103,1.776347073775019,37.84228539879187,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-08,0.09099999815225601,0.09279999881982803,0.08980000019073486,0.09239999949932098,574187,0.0,0.0,0.09368529990315437,0.14950984995812178,0.1482782833899061,-1.371933916166191,-37.33837608064221,0.8305778432686685,37.958015176740645,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-09,0.09260000288486481,0.09539999812841415,0.09099999815225601,0.09359999746084213,1200648,0.0,0.0,0.09402769953012466,0.14742484986782073,0.1477932833135128,-0.45486816270082064,-36.21991162654823,-0.24928970886350282,38.69555599867678,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-12,0.0949999988079071,0.10700000077486038,0.0949999988079071,0.09700000286102295,1693086,0.0,0.0,0.09532409980893135,0.14539984986186028,0.14743494999905427,1.7581105464943279,-34.440028721146746,-1.3803376588841687,40.841418610107404,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-13,0.09799999743700027,0.10499999672174454,0.09719999879598618,0.10100000351667404,2078916,0.0,0.0,0.09652160033583641,0.14357485007494689,0.14716995004564523,4.639793751093549,-32.77262676196312,-2.442822036416615,43.353580141246795,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-14,0.10100000351667404,0.10100000351667404,0.09719999879598618,0.09799999743700027,1106698,0.0,0.0,0.09711209982633591,0.1416498500853777,0.14690328339735667,0.9143017319697325,-31.442144296091527,-3.576117014191597,41.91592212490049,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-15,0.10300000011920929,0.10300000011920929,0.09560000151395798,0.09740000218153,934658,0.0,0.0,0.09676000028848648,0.1379848500713706,0.14667995007087786,0.6614322975768628,-29.87635944204105,-5.927940386743838,41.61866713398312,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-16,0.10100000351667404,0.10100000351667404,0.0934000015258789,0.09520000219345093,410155,0.0,0.0,0.09598000049591064,0.1343273499980569,0.1463416167224447,-0.8126675332669402,-28.54768556269514,-8.20974032778001,40.48495362354942,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-19,0.09520000219345093,0.10000000149011612,0.09260000288486481,0.09480000287294388,2978710,0.0,0.0,0.095660001039505,0.13087235018610954,0.14598828343053658,-0.8990154267361659,-26.905873621532844,-10.354209864807009,40.270160795168884,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-20,0.09839999675750732,0.09839999675750732,0.09279999881982803,0.0949999988079071,1301908,0.0,0.0,0.095660001039505,0.125747349858284,0.14570328344901404,-0.6899458754190659,-23.92682537857628,-13.696282690645893,40.44030813800027,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-21,0.09019999951124191,0.09719999879598618,0.09019999951124191,0.09560000151395798,1097123,0.0,0.0,0.09600000083446503,0.12126234974712133,0.14508828340719143,-0.41666595523970607,-20.83280504240436,-16.421680028567454,40.983463743914946,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-22,0.10000000149011612,0.1185000017285347,0.09200000017881393,0.0957999974489212,2739246,0.0,0.0,0.09634000062942505,0.11635734979063272,0.14451495005438725,-0.5605181409339877,-17.2033388498671,-19.484212708206034,41.176029386311804,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-23,0.10300000011920929,0.1054999977350235,0.09160000085830688,0.09399999678134918,786229,0.0,0.0,0.09638000056147575,0.11123234983533621,0.14386995006352662,-2.4693958977604344,-13.352544737072686,-22.68548797978945,39.913726587316624,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-26,0.09000000357627869,0.0997999981045723,0.08579999953508377,0.09040000289678574,1341714,0.0,0.0,0.09572000056505203,0.10630485005676746,0.14317161676784357,-5.557874672859812,-9.95707108947809,-25.750052659429358,37.44151160425565,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-27,0.09019999951124191,0.09279999881982803,0.08619999885559082,0.09220000356435776,688394,0.0,0.0,0.0948400005698204,0.10485984999686479,0.14253661675999563,-2.78363242260749,-9.555468015016203,-26.43304409741344,39.46061044807749,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-28,0.09780000150203705,0.09780000150203705,0.09000000357627869,0.0949999988079071,490003,0.0,0.0,0.09454000070691108,0.10400985013693571,0.1419532833620906,0.48656452036856535,-9.104762113931478,-26.72952137948778,42.565956727101344,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-30,0.09179999679327011,0.09799999743700027,0.08760000020265579,0.08760000020265579,1404004,0.0,0.0,0.09356000050902366,0.10325985010713339,0.14122661675016085,-6.3702439866842875,-9.393631298172531,-26.883577272259636,37.143306548686475,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-02,0.08760000020265579,0.09480000287294388,0.08320000022649765,0.08860000222921371,1927209,0.0,0.0,0.09290000051259995,0.10257985014468432,0.1405466167256236,-4.6286310652958775,-9.436404536009144,-27.01364676394762,38.28743998453886,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-03,0.08839999884366989,0.09300000220537186,0.08399999886751175,0.09300000220537186,711919,0.0,0.0,0.09272000044584275,0.10206985026597977,0.13990328336755434,0.30198636559827857,-9.160246434939033,-27.04256268394964,43.18754284391713,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-04,0.09300000220537186,0.09780000150203705,0.08699999749660492,0.09719999879598618,1038760,0.0,0.0,0.09294000044465064,0.10154485031962394,0.13921828338255485,4.583600528248893,-8.473940182971916,-27.060693572415996,47.474806953279035,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-05,0.0997999981045723,0.10350000113248825,0.09019999951124191,0.09939999878406525,891645,0.0,0.0,0.09332000017166138,0.10086985044181347,0.1386349499846498,6.5152149605869685,-7.484744189748953,-27.24067743885495,49.61946409031779,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-09,0.09600000083446503,0.0997999981045723,0.08500000089406967,0.09719999879598618,568193,0.0,0.0,0.09346000030636788,0.10033735036849975,0.1380232833325863,4.001710333146098,-6.854227301073889,-27.304040343162278,47.52950313589628,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-10,0.09700000286102295,0.09700000286102295,0.08839999884366989,0.09279999881982803,1005864,0.0,0.0,0.09334000051021576,0.09971985034644604,0.13712994996458291,-0.5785319128304803,-6.397773175616932,-27.280765163116392,43.57628328315219,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-11,0.09000000357627869,0.094200000166893,0.08820000290870667,0.094200000166893,585437,0.0,0.0,0.09372000023722649,0.09911235030740499,0.13629994994650285,0.5121638161027859,-5.440643929292055,-27.2836487861469,45.139810549218296,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-12,0.09279999881982803,0.09440000355243683,0.08980000019073486,0.09080000221729279,145803,0.0,0.0,0.09358000010251999,0.09841985031962394,0.13544994996239743,-2.9707179762573452,-4.917554945863329,-27.338584955589496,42.08944522600755,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-13,0.09080000221729279,0.11550000309944153,0.09059999883174896,0.09539999812841415,588082,0.0,0.0,0.09362000003457069,0.09770485032349825,0.13470328326026598,1.90130110359557,-4.180806045352639,-27.46661554290512,47.280187367690935,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-16,0.0934000015258789,0.0934000015258789,0.09120000153779984,0.09120000153779984,44404,0.0,0.0,0.0939800001680851,0.09680985026061535,0.1338466165587306,-2.958074723678631,-2.9231014043635075,-27.67105157407088,43.450667249738736,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-17,0.09120000153779984,0.09120000153779984,0.08540000021457672,0.09120000153779984,568741,0.0,0.0,0.0942400000989437,0.096114850230515,0.13295328319072724,-3.225804921426293,-1.9506352317823792,-27.707802376994273,43.450667249738736,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-18,0.08560000360012054,0.0949999988079071,0.08320000022649765,0.0868000015616417,1392818,0.0,0.0,0.09362000003457069,0.09515985026955605,0.1321849498276909,-7.28476657809293,-1.6181721919732734,-28.010071953273624,39.55779342503055,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-19,0.08560000360012054,0.1145000010728836,0.07519999891519547,0.09099999815225601,2707359,0.0,0.0,0.09299999997019767,0.09443485029041768,0.1315216165035963,-2.1505395898737323,-1.5194076295005248,-28.1982287011843,44.65501055155536,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-23,0.09099999815225601,0.10450000315904617,0.08139999955892563,0.0966000035405159,8805681,0.0,0.0,0.09272000044584275,0.09383735042065382,0.13099494992444913,4.1846452502331895,-1.190730524468365,-28.365673276126923,50.632982875984446,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-24,0.10000000149011612,0.10249999910593033,0.09260000288486481,0.09719999879598618,4279982,0.0,0.0,0.09272000044584275,0.0940513253211975,0.13065661663810413,4.831749707292301,-1.4155301595252467,-28.016408398433313,51.24066632485155,,,-2.62481,-1.82582,-1.06611,,0.49340102,,Lipigon Pharmaceuticals AB (publ),Healthcare,"Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden."
